

Sannamycin-Type Aminoglycoside Antibiotics – Efficient Syntheses – Biological Activity

Silke Erbeck, Xifu Liang, Dieter Hunkler, Richard Krieger, and Horst Prinzbach*

Chemisches Laboratorium der Universität Freiburg i. Br., Institut für Organische Chemie und Biochemie, Albertstraße 21, D-79104 Freiburg i. Br., Germany

Received April 14, 1998

Keywords: Sannamycin-type antibiotics / Aminoglycoside syntheses / Glycosylation / Biological activity

Shorter and more efficient routes to 6'-des(*N*-methyl)sannamycin A (**1**) and its 2'-*epi* analog **2** have been elaborated with the proven sannamine-type acceptor **10** and the glycosyl donors **5–8** featuring novel protecting patterns.

With glycal **9** as glycosyl donor (and **10**) an expedient access to 2'-desamino- (**3**) and 2'-desamino-2'-*epi*-hydroxysannamycin A (**4**) has been opened. For **4** a modest antibacterial activity was found, while **3** was inactive.


Introduction

In continuation of earlier work directed towards the total synthesis of binuclear aminoglycoside antibiotics^[1], efficient routes to (2'-*epi*-)purpurosamine-type glycosyl donors, e.g. the naturally configured **5–8** (D, 5-*R*), have been presented in a preceding paper^[2]. The novel *N*-protection patterns {2'-sulfonamido-, 2'-trifluoroacetyl-amino-, 2'-azido-, 6'-[trifluoroacetyl-(1*R*)-phenylethyl]amino-, 6'-azido-} of these donors were expected to be better suitable for the subsequent synthetic demands (glycosylation, protection/deprotection)^[1] and thus to make these routes more economical. In this paper we present the application of the donors **5–8**^[2] and of the sannamine-type acceptor **10**^[3] for the construction of 6'-des(*N*-methyl)sannamycin A (**1**)^{[1][4]} and its 2'-*epi* isomer **2**^[1]. Included are routes to the structurally modified sannamycins A **3** and **4** featuring the I⁺-mediated addition of **10** to glycal **9** as key step. Structural variations at C-2' such as desamination (**3**) or hydroxylation (**4**) have been repeatedly reported to induce biological activity^[5] at lower toxicity^[6].

Glycosylations

The glycosylations in our prior syntheses had generally been effected under Koenigs-Knorr conditions with TMSOTf as promotor, allowing for yields ranging from 51 to 91% and α/β ratios from 1.8:1 to 13:1^[1]. In exploratory experiments the novel donors **5** (2'- α -benzenesulfonamido) and **6** (2'-trifluoroacetyl-amino) were found not to be sufficiently tolerant to the above promotor. The desired α -glycosides **11** ($[\alpha]_D^{25} = +36.4$) and **12** ($[\alpha]_D^{25} = +34.5$) were isolated in only moderate yields of 30–45% along with residual acceptor and other α -glycosidic components. Partial dealkylation at 6'-N and epimerization at C-2' are responsible for some of the side products. There was generally no hint for the formation of β -glycosides (TLC, ¹H-NMR, < 3%).


With BF₃·OEt₂ as a milder promotor these complications could be largely avoided. Irrespective of the N-func-



tionality in the three donors **5–7** the treatment with the acceptor **10** under the specified set of conditions (Scheme 1) provided selectively (80–85%, TLC, ¹H NMR) the α -glycosides **11–13**, which were chromatographically purified


without significant material loss from still minor fractions containing α -glycosidical and glycon components. Even in larger runs (mmolar scale) again no β -glycosides were detected by careful reaction control (TLC, ^1H NMR).

Scheme 1. i) Donor (1.0 equiv.)/acceptor (1.2 equiv.)/ $\text{BF}_3 \cdot \text{OEt}_2$ (1.2 equiv.)/anhydrous CH_2Cl_2 , N_2 atm., 1 h, room temp.



The change in stereochemistry at C-2' in the 2'- β -azido donor **8** had no profound consequences for the reaction with donor **10**. Yet, besides ca. 70% of the wanted α -glycoside **14** very small amounts (< 5%) of β -glycoside **15** were identified in the crude reaction mixture and chromatographically isolated.

Scheme 2. i) Donor (1.0 equiv.)/acceptor (1.2 equiv.)/ $\text{BF}_3 \cdot \text{OEt}_2$ (1.2 equiv.)/anhydrous CH_2Cl_2 , 1 h, N_2 , room temp.



6'-Des(*N*-methyl)sannamycin A (1)

On the way from the differently protected glycosides **11**, **12**, and **13** to the target **1** the general synthetic problem consisted in the sequence and in the selectivity of the deprotection (four N, one O functions) and *N*-glycylation steps.

Glycoside **11** fell out of the competition when the NH-SO₂Ph cleavage posed insurmountable difficulties at whatever stage in the synthetic route. For **12**, in contrast, the first explored sequence^[1] via the intermediate trisamine **18a** (**18b**) proved highly economical: The threefold deprotection **12** $\rightarrow$ **16** $\rightarrow$ **17a** $\rightarrow$ **18a** was simply and nearly quantitatively achieved by heating **12** in a 3% aqueous NaOH

solution for a longer period of time. The rates of the individual deprotection steps turned out as sufficiently distinct as to allow the selective generation, isolation and identification of the intermediates **16** and **17a**: In 3% methanolic NaOH/water (1:1) at room temperature in **12** the 2'-trifluoroacetyl amino group was exclusively removed to give 95% of **16**. Refluxing for 4 h was needed in order to totally and neatly hydrolyze the carbamate ring to give 94% of **17a**. In this medium only after 40 h refluxing the sterically protected 6'-trifluoroacetyl amino group had been totally saponified (91% of **18a** isolated). The amines **16**, **17a**, and **18a** – after extractive work-up – were present in such a uniform state that no further purification was necessary; they were transformed into the *Z* derivatives **18b** and **19b** in a standard way.

In spite of the highly economical access to **18a** (**18b**) the published procedure to **1**^[1], implying labor-intensive differentiation of the *Z*-protected amino functions, was not pursued any further, when it was found that under reductive conditions ($\text{NaBH}_4/\text{EtOH}$) neat deprotection in **12** at 2'-N and 6'-N to diamine **19a** was possible (87% isolated). In the bis-*Z* derivative **19b** the carbamate ring was neatly hydrolyzed in refluxing $\text{Ba}(\text{OH})_2/\text{dioxane/water}$, without any noticeable involvement of the NH-*Z* groups. In **20** (88%) the stage was set for the relatively slow but nevertheless rather selective *N*-glycylation to yield 81% of **21** ($[\alpha]_{\text{D}}^{25} = +86.3$). After standard, one-pot catalytic reduction – $\text{N}_3 \rightarrow \text{NH}_2$ hydrogenation, NH-*Z* and NZR* hydrogenolysis – tetramine **1** was isolated as tetrakis(hydrochloride) (^1H NMR, ^{13}C NMR, IR). The average overall yield of 55% for the five operations starting from **12** very favorably compares with the 22% for the much more laborious alternative of Scheme 6 in ref.^[1].

Diazidoglycoside **13** had figured as substitute for **12** in case that the latter's kind of protection at 6'-N would pose problems. In fact, the deprotection to give **22** was straightforward under the basic as well as the reductive conditions which had been applied to **12** (93%, quant.). It needs no further comment that **22** in close analogy to the sequence **19** $\rightarrow$ **1** could serve as precursor of the latter.


2'-*epi*-6'-Des(*N*-methyl)sannamycin A (2)

With the three 4-, 2'-, 6'-N functions in the 2'-*epi* donor **14** "protected" as azides, the synthesis of the 2'-*epi*-des(*N*-methyl)sannamycin **2** indeed turned out unproblematic (Scheme 4). After only three standard operations – basic carbamate cleavage ($\rightarrow$ **23**), *N*-glycylation ($\rightarrow$ **24**), and one-pot fourfold deprotection by hydrogenolysis – the salt **2**·4 HCl (^1H NMR, ^{13}C NMR, IR, MS) was obtained in an overall yield of 64% based on **14**. For comparison: With the 6'-NHDNP analog of **14** as precursor, the overall yield had been as low as 8% (Scheme 8 in ref.^[1]).


2'-Desaminosannamycin A (3)

The synthetic sequence followed for the 2'-desaminated sannamycin A (**3**, Scheme 5), in principle, implies the I^+ -mediated linking of enantiomerically pure glycal **9**^[7] with

Scheme 3. (i) 3% methanolic NaOH/water (1:1), 1.25 h, room temp., 95%. – (ii) analogous to (i), 4 h, reflux, 94%. – (iii) *Z*-*O*-suc/DMF, room temp, 20 h. – (iv) analogous to (i), 40 h, reflux, 91%. – (v) NaBH₄/ethanol, room temp., 22 h, 87%. – (vi) ZCl (2.4 equiv.)/NaHCO₃/acetone/water (1:1), room temp., 94%. – (vii) Ba(OH)₂ (5 equiv.)/dioxane/water (2:1), reflux, 8 h, 88%. – (viii) *Z*-gly-*O*-suc/DMF, 60°C, 26 h, 81%. – (ix) methanol/2 N HCl/H₂ (1 atm)/10% Pd/C, 28 h, 95%




acceptor **10**, 6'-*N*-methylation, the reductive elimination of the introduced iodine, and *N*-glycylation. In line with earlier reports, the reaction of **9** with **10** in the presence of NIS (*N*-iodosuccinimide, **25**^[8]) in acetonitrile led stereoselec-



tively (¹H NMR, TLC) to the aspired 2β-iodo-α-glycoside **27** isolated as colorless solid ([α]_D²⁵ = +12.3) but only in 42% yield – together with an even larger proportion of the succinimide adduct **33** (51%); no 1'β,2'α isomer **32** was detectable. With [I(*sym*-coll)₂]ClO₄ (**26**) as I⁺ source – being provided with a less nucleophilic counter ion – in CH₂Cl₂ as solvent **27** was generated in higher yield (> 60%) – now, however, accompanied by significant amounts (25–30%) of isomer **32**. Change to CH₃CN as solvent improved the **27**/**32** ratio to ca. 7:1 but introduced the iodo olefin **34** as additional product: From an exploratory experiment chromatographically 60% of **27**, 8% of **32**, and

Scheme 4. (i) 3% methanolic NaOH/water (1:1), reflux, 2 h, 94%. – (ii) *Z*-gly-*O*-suc/DMF, 50°C, 16 h, 68%. – (iii) methanol/2 N HCl/H₂ (1 atm)/10% Pd/C, 2 h, quant.




21% of **34** were obtained (together with traces of “dimeric adducts”^[2]). It was established that the glycosides **27** and **32** are stable under the given conditions and that the olefin **34** arises solely from donor **9** presumably by deprotonation in the intermediate iodonium ion(s). Ultimately after switching to a 2:1 mixture of CH₂Cl₂/CH₃CN as solvent, from runs taken to total conversion, 70–75% of **27** and 13–17% of **32** and only trace quantities of **34** were isolated.

For the subsequent methylation at 6'-N to give **29** first the trifluoroacetyl group was taken off from **27** with NaBH₄ in ethanol to afford 87% of **28**. In the latter, the sterically demanding R* group necessitated rather forcing conditions for the methylation, what favored quaternization to the ammonium ion **35**. As a compromise **28** was taken to partial conversion: With a large excess (20 equivalents) of CH₃I at room temperature and with ca. 20% of **28** left, 70–75% of monomethylamine **29** (no **35**) were secured. Variation of the reaction conditions [even larger excess of CH₃I, higher temperature (60°C), dimethyl sulfate as alkylating agent] had no favorable effects on the relative rates (**28** → **29** → **35**). Carbamate hydrolysis and HI elimination were effected as a one-pot procedure and gave nearly quantitatively olefin **30** ([α]_D²⁵ = +8.1). After *N*-glycylation (→ **31**), saturation of the C=C double bond and “deprotection” at 4-N and 6'-N were effected through standard catalytic hydrogenolysis. The overall yield of trishydrochloride **3** amounted to 40–45% for the five operations starting from **27**.

2'-Desamino-2'-epi-hydroxysannamycin A (4)

With the 2'β-iodide **27** now available, its utilization for the synthesis of the so far unknown 2'-desamino-2'-epi-hydroxysannamycin A became an attractive project. In exploratory experiments it became, however, rapidly and not unexpectedly clear, that iodine → hydroxy substitution in

Scheme 5. (i) **25** (1.5 equiv.)/CH₃CN, room temp. 2 h, 42%. – (i') **26** (1.5 equiv.)/CH₂Cl₂/CH₃CN (2:1), room temp., 12 h, 72%. – (ii) NaBH₄/ethanol, room temp. 6 h, 87%. – (iii) CH₃I (20 equiv.)/K₂CO₃/CH₃CN, room temp. 2 h, 72%. – (iv) 3% methanolic NaOH/water (1:1), reflux, 2 h. – (v) *Z*-gly-*O*-suc/DMF, 70°C, 20 h, 77%. – (vi) methanol/2 N HCl/H₂ (1 atm)/10% Pd/C, 9 h, 94%



27, competing with β -HI elimination, neither under S_N2 - nor S_N1 -like conditions could be effected with satisfying selectivity. In order to probe the stereochemical course of radical substitution by oxygen^[9], **27** was treated in benzene (50°C, 48 h) with Bu_3SnH , oxygen gas being continuously blown through the solution – with a non-acceptable result. After reduction with $NaBH_4$ (methanol) 37% of 2' β -ol **42**, 8% of 2' α -ol **43**, and 42% of reduced **44** were chromatographically separated from other, small components. For the interception of the intermediate C-2' radical TEMPO^[10] proved to be the reagent of choice: Besides ca. 80% of the 2' β -adduct **36** (m.p. 63°C), only small quantities of the 2' α isomer **45** (m.p. 66–68°C, 4%) and of reduced **46** (6%) were obtained. The gratifyingly high α/β ratio of ca. 20:1 presumably reflects above all steric hindrance towards the bulky TEMPO reagent approaching from the α side.

Under the standard conditions for the N–O cleavage in **36** simultaneously or even faster the 4-azido function was reduced; such a one-pot treatment furnished after chromatography 84% of the 2 β -hydroxy-4 β -amine **37a**. When the reaction was stopped at an intermediate stage 63% of the 4-amino derivative **47** were found along with 26% of **37a**. After protection in **37a** of the 4-NH₂ function in form of its *Z* derivative **37b** ($[\alpha]_D^{25} = +29.3$), the ensuing reaction sequence ending with 4·3 HCl was performed as practiced with **3**. After deprotection at 6'-N (**38**) the subsequent methylation provided 70% of **39**, carbamate hydrolysis 92% of **40**. *N*-glycylation (78% of **41**) and one-pot twofold hydrogenolysis (94%) gave 4·3 HCl with an overall yield of 25% for the eight operations starting from iodide **27a**.


Analytical Data

For all the glycosides pictured in Schemes 1–6 the configurational and conformational details directly follow from the mostly fully assigned ¹H-NMR, ¹³C-NMR (homo/heteronuclear decoupling and NOE experiments), IR, and in part FAB mass spectra. In view of the generally close analogy with the earlier analyses^{[1][4]}, no detailed discussion is necessary; some representative NMR assignments are given in Figure 1. The sugar parts irrespective of the kind of substitution at C-2' – except for **30** – expectedly prefer a ⁴C₁ chair, the protected aglycon parts of **12** and **27** the half-chair conformation with quasi equatorial 3-O and 4-azido, quasi-axial 6-OCH₃ functions. The 1a,2e,3e,4e,6a-chair of **30** and **40** expectedly changes into the 1e,2a,3a,4a,6e-chair of 3·3 HCl and 4·3 HCl bringing the voluminous *N*-glycylated amino group into the equatorial position.


Biological Activity

The glycosides **3** and **4** have been subjected as hydrochlorides to the earlier specified agar diffusion tests against a selection of Gram-positive and Gram-negative bacteria (Table 1). For **3** no activity was found. For **4** the minimal inhibitory concentrations (MIC) are again compared with those determined for a commercial mixture of Gentamicin C₁, C_{1a}, C₂ sulfates (Refobacin); there is activity but clearly less than in the case of the amino analog **2**.^[1]

Scheme 6. (i) TEMPO (3.0 equiv.)/ Bu_3SnH (2 equiv.)/benzene, reflux, 4.5 h, 78%. – (ii) $Zn/HOAc$, room temp., 40 h, 84%. – (iii) *Z*-*O*-suc (1.2 equiv.)/DMF, room temp., 14 h, 95%. – (iv) $NaBH_4/EtOH$, room temp., 4 h, 86%. – (v) CH_3I (20 equiv.)/ K_2CO_3/CH_3CN , room temp., 2 h, 70%. – (vi) 3% methanolic $NaOH$ /water (1:1), reflux, 2 h, 92%. – (vii) *Z*-gly-*O*-suc (1.3 equiv.)/DMF, 60°C, 28 h, 78%. – (viii) methanol/2 *N* HCl/ H_2 (1 atm)/10% Pd/C, 8 h, 94%



	42	43	44	45	46	47
R ¹	H	H	H	COCF ₃	COCF ₃	COCF ₃
R ²	OH	H	H	H	H	TEMPO
R ³	H	OH	H	TEMPO	H	H
R ⁴	N ₃	N ₃	N ₃	N ₃	N ₃	NH ₂

Figure 1. ^1H - and ^{13}C -NMR assignments [δ , J (Hz), CDCl_3 (**12**, **27**, **30**, **40**), D_2O (**3**·**3** HCl, **4**·**3** HCl)]Table 1. Minimal inhibitory concentration (MIC, $\mu\text{g}/\text{ml}$ free base)

Organism	4	Refobacin
<i>Escherichia coli</i> ATCC 25922	78	0.56
<i>Staphylococcus aureus</i> SG 511	78	0.28
<i>Staphylococcus aureus</i> ATCC 25923	78	0.28
<i>Serratia marcescens</i> E 8382/92 ^[a]	39	0.56
<i>Pseudomonas maltophilia</i> D 141/92 ^[a]	—	1.12
<i>Pseudomonas aeruginosa</i> ATCC 27853	—	1.12
<i>Bacillus subtilis</i> ATCC 6633	9.75	0.017
<i>Acinetobacter baumannii</i> H 5250/92 ^[a]	—	72
<i>Staphylococcus aureus</i> H 5248/92 ^[a]	—	0.07
<i>Enterococcus faecalis</i> D 1160/93 ^[a]	—	9
<i>Enterobacter aerogenes</i> D 1088/93 ^[a]	39	0.28
<i>Salmonella enteritidis</i> ^[a]	78	0.28
<i>Shigella sonnei</i> ATCC 11060	—	0.56
<i>Citrobacter freundii</i> E 8737/90 ^[a]	78	0.28
<i>Morganella morganii</i> H 1962/93 ^[a]	78	0.28
<i>Klebsiella pneumoniae</i> ATCC 27736	78	0.56
<i>Staphylococcus saprophyticus</i> RV 2/87	9.75	0.36
<i>Corynebacterium diphtheriae</i>	19.5	0.07
<i>Staphylococcus epidermidis</i> E 266/92 ^[a]	19.5	0.017
<i>Streptococcus sanguis</i> D 25/88 ^[a]	—	1.12

^[a] Recent clinical isolates from Freiburg.

Support by the *Deutsche Forschungsgemeinschaft*, the *BASF AG*, and the *Fonds der Chemischen Industrie* is gratefully acknowledged. We thank Dr. J. Wörth for MS analyses, Dr. K. Pelz and A. Wittmer, *Institut für Hygiene und Mikrobiologie der Universität Freiburg*, for advice with the biological tests. X. L. thanks the *National Education Committee, People's Republic of China*, for financial support.

Experimental Section

Melting points: Monoskop IV (Fa. Bock), uncorrected. — Elemental analyses: Analytische Abteilung des Chemischen Laboratoriums Freiburg i. Br. — IR spectra: Perkin-Elmer 457 or Philips PU 9706. — ^1H NMR: Bruker AC 250, AM 400; ^{13}C NMR: Bruker

AM 400. Chemical shifts are given relative to TMS ($\delta = 0$), coupling constants in Hz; if not specified otherwise, the 400-MHz (^1H) and 100.6-MHz (^{13}C) spectra recorded in CDCl_3 are given; values marked with an asterisk are interchangeable. — Mass spectra: Finnigan MAT 44S (EI 70 eV, if not specified differently), Finnigan MAT 312 (FAB-Gun Microbeam-7, 6 kV, Xenon, matrix: *m*-nitrobenzyl alcohol), or Finnigan TSQ 7000 (syringe pump: 2 $\mu\text{l}/\text{min}$, spray 4–5 kV). — Optical rotations: PE 241 polarimeter; specific rotation values are given in units of $10^{-1} \text{ deg cm}^2 \text{ g}^{-1}$. — TLC: silica gel plates 60 F₂₅₄ (Merck, Darmstadt). — The silica gel used for column chromatography was Merck (0.040–0.063 mm) or ICN-Silica, ICN, Biomedicals GmbH (0.032–0.063 mm). — The purity of oily compounds has generally been confirmed by careful TLC and NMR control; in many cases elemental analyses turned out to be erratic.

General Procedures. — **Glycosylation (GP 1):** A solution of glycosyl donor (0.30 mmol) and aglycon (0.36 mmol) in anhydrous CH_2Cl_2 was treated with $\text{BF}_3 \cdot \text{OEt}_2$ (0.36 mmol) under N_2 at room temp. After stirring for 1 h, the reaction mixture was quenched with saturated NaHCO_3 solution and the aqueous layer extracted with CH_2Cl_2 . The combined organic phases were dried (MgSO_4) and concentrated in vacuo; the pure glycoside was obtained by chromatography on silica gel with the eluent specified.

N-Glycylation (GP 2): A solution of glycoside (0.05 mmol) and *Z*-gly-*O*-suc (0.06 mmol) in DMF was stirred at 60°C until total conversion. The solvent was removed in vacuo and the residue chromatographed on silica gel with the eluent specified.

Hydrogenolysis (GP 3): A solution of glycoside (0.02 mmol) in methanol (10 ml) and 2 N HCl (0.1 ml) was treated with H_2 in the presence of 10% Pd/C under atmospheric pressure at room temp.; the catalyst was removed by filtration and the filtrate concentrated in vacuo.

4-Azido-3-*O*-[2'-*α*-benzenesulfonamido-6'-{trifluoroacetyl}[(1*R*)-phenylethyl]]amino-2',3',4',6'-tetra-deoxy- α -D-hexopyranosyl]-1-*N*,2-*O*-carbonyl-1,4,5-trideoxy-6-*O*-methyl-1-methylamino-*L*-chiro-inositol (11): **5** (100 mg, 0.19 mmol) and **10** (56 mg, 0.23 mmol)

were converted according to GP 1 [$\text{BF}_3 \cdot \text{OEt}_2$ (34 μl , 0.27 mmol)] to yield after chromatography [$\text{CH}_2\text{Cl}_2/\text{acetone}$, 10:1, R_f (**11**) = 0.49, R_f (**10**) = 0.13] **11** (108 mg, 80%) as colorless oil. $[\alpha]_{\text{D}}^{25} = +36.4$ ($c = 0.1$, CHCl_3). – IR (KBr): $\tilde{\nu} = 3285 \text{ cm}^{-1}$ (NH), 2107 (N_3), 1764 (NCOO), 1665 ($6'\text{-NR}^*\text{COCF}_3$), 1329 (NHSO_2), 1164 (NHSO_2). – ^1H NMR: $\delta = 7.88$ (m, 2 H), 7.55 (m, 3 H), 7.36 (m, 3 H), 7.26 (m, 2 H), 5.27 (q, $1''\text{-H}$), 5.18 (d, $1'\text{-H}$), 4.82 (d, N-H), 4.35 (dd, 2-H), 4.10 (m, $5'\text{-H}$), 3.71 (dd, 1-H), 3.72–3.55 (m, 3-, 4-, 6-H), 3.41 (s, OCH_3), 3.34 (m, $2'\text{-H}$), 3.18 (dd, $6'\text{-a-H}$), 2.80 (s, NCH_3), 2.58 (dd, $6'\text{-b-H}$), 2.18 (ddd, $5\alpha\text{-H}$), 1.68–1.46 (m, $5\beta\text{-}$, $4'\alpha\text{-H}$, $3'\text{-H}_2$), 1.65 (d, $2''\text{-H}$), 1.10 (dddd, $4'\beta\text{-H}$); $J_{1',2'} = 3.5$, $J_{2',\text{NH}} = 9.9$, $J_{5',6'\text{a}} = 1.6$, $J_{5',6'\text{b}} = 8.3$, $J_{6'\text{a},6'\text{b}} = 14.2$, $J_{1'',2''} = 6.9$, $J_{1,2} = J_{2,3} = 7.5$, $J_{1,6} = 2.1$, $J_{4,5\alpha} = J_{5\alpha,6} = 4.0$, $J_{5\alpha,5\beta} = 14.7$ Hz. – ^{13}C NMR: $\delta = 157.9$ (C=O), 141.2 (C_s , PhSO_2NH), 138.7 (C_s), 132.8–126.8 (10 C), 116.9 (q, COCF_3), 94.5 ($\text{C-1}'$), 77.8 (C-2), 77.1 (C-3), 73.8 (C-6), 65.3 (C-5'), 60.9 (C-1), 57.1 (C-4), 56.5 (OCH_3), 55.4 (C-1''), 51.5 (C-2'), 49.0 (C-6'), 30.4 (NCH_3), 28.4, 28.2, 25.3 (C-5, C-4', C-3'), 17.9 (C-2''); $J_{\text{C,F}} = 287.8$ Hz. – MS (FAB); m/z (%): 733 (1) [$\text{M} + \text{Na}$] $^+$, 711 (5) [$\text{M} + \text{H}$] $^+$, 607 (3) [$\text{M} - \text{R}^*$, + 2 H] $^+$, 569 (2) [$\text{M} - \text{SO}_2\text{C}_6\text{H}_5$] $^+$, 469 (14) [$\text{C}_{22}\text{H}_{24}\text{N}_2\text{O}_4\text{SF}_3$] $^+$.

4-Azido-3-O-[2'-a-trifluoroacetyl-amino-6'-{trifluoroacetyl}[(1R)-phenylethyl]]amino-2',3',4',6'-tetra-deoxy- α -D-hexopyranosyl]-1-N,2-O-carbonyl-1,4,5-tri-deoxy-6-O-methyl-1-methylamino-L-chiro-inositol (12**):** **6** (500 mg, 1.03 mmol) and **10** (300 mg, 1.24 mmol) were converted according to GP 1 [$\text{BF}_3 \cdot \text{EtO}_2$ (150 μl , 1.18 mmol)] to yield after chromatography [$\text{CH}_2\text{Cl}_2/\text{acetone}$, 20:1, R_f (**12**) = 0.33, change of solvent $\text{CHCl}_3/\text{MeOH}$, 10:1, R_f (**10**) = 0.45] **12** (519 mg, 80%) as colorless oil and residual **10** (42 mg, 14%). [Four further fractions were eluted ($\text{CH}_2\text{Cl}_2/\text{acetone}$, 20:1): $R_f = 0.56$ (27 mg) mixture of glycon derivatives; $R_f = 0.48$ (38 mg), $R_f = 0.18$ (35 mg) and $R_f = 0.10$ (46 mg), the latter three contained mixtures of α -glycosides.] $[\alpha]_{\text{D}}^{25} = +34.5$ ($c = 0.2$, CHCl_3). – IR (KBr): $\tilde{\nu} = 3356 \text{ cm}^{-1}$ (NH), 2114 (N_3), 1755 (NCOO), 1689 ($2'\text{-NHCOCF}_3$, $6'\text{-NR}^*\text{COCF}_3$), 1560 ($2'\text{-NHCOCF}_3$). – ^1H NMR: $\delta = 7.33$ (m, 5 H), 6.40 (d, NH), 5.34 (d, $1'\text{-H}$), 5.26 (q, $1''\text{-H}$), 4.41 (dd, 2-H), 4.23 (m, $5'\text{-H}$), 4.06 (m, $2'\text{-H}$), 3.78 (dd, 1-H), 3.80–3.65 (m, 6-, 4-, 3-H), 3.45 (s, OCH_3), 3.25 (dd, $6'\text{-a-H}$), 2.82 (s, NCH_3), 2.68 (dd, $6'\text{-b-H}$), 2.26 (ddd $5\alpha\text{-H}$), 1.90–1.55 (m, $5\beta\text{-}$, $4'\alpha\text{-H}$, $3'\text{-H}_2$), 1.21 (dddd, $4'\beta\text{-H}$); $J_{1',2'} = 3.8$, $J_{2',\text{NH}} = 9.1$, $J_{3'\beta,4'\beta} = 4.6$, $J_{3'\alpha,4'\beta} = J_{4'\alpha,4'\beta} = J_{4'\beta,5'} = 12.6$, $J_{5',6'\text{a}} = 1.6$, $J_{5',6'\text{b}} = 8.3$, $J_{6'\text{a},6'\text{b}} = 14.2$, $J_{1,2} = J_{2,3} = 7.2$, $J_{1,6} = 2.7$, $J_{5\alpha,5\beta} = 14.5$, $J_{4,5\alpha} = J_{5\alpha,6} = 3.5$ Hz. – ^{13}C NMR: $\delta = 157.3$ (C=O), 156.7 (C=O), 138.6 (C_s), 128.9 (C_m), 128.2 (C_o), 127.2 (C_p), 116.9 [q, COCF_3 , (C-6')], 115.8 [q, COCF_3 , (C-2')], 94.4 (C-1'), 78.1 (C-2), 77.4 (C-3), 73.7 (C-6), 65.5 (C-5'), 61.1 (C-1), 57.2 (OCH_3), 56.3 (C-4), 55.5 (C-1''), 49.1 (C-2'), 48.0 (C-6'), 30.4 (NCH_3), 28.7 (C-5), 27.6 (C-4'), 23.8 (C-3'), 17.9 (C-2''); $J_{\text{C,F(C-2')}} = J_{\text{C,F(C-6')}} = 287.5$ Hz. – MS (FAB); m/z (%): 689 (8) [$\text{M} + \text{Na}$] $^+$, 667 (29) [$\text{M} + \text{H}$] $^+$, 563 (54) [$\text{M} - \text{R}^*$, + 2 H] $^+$, 425 (23) [$\text{C}_{18}\text{H}_{19}\text{F}_6\text{O}_3\text{N}_2$] $^+$, 321 (38) [$\text{C}_{18}\text{H}_{19}\text{F}_6\text{O}_3\text{N}_2 - \text{R}^*$, + H] $^+$, 243 (51) [$\text{C}_9\text{H}_{13}\text{O}_4\text{N}_4 + 2 \text{H}$] $^+$, 105 (100) [R^*] $^+$.

4-Azido-3-O-[6'-azido-2'-a-trifluoroacetyl-amino-2',3',4',6'-tetra-deoxy- α -D-hexopyranosyl]-1-N,2-O-carbonyl-1,4,5-tri-deoxy-6-O-methyl-1-methylamino-L-chiro-inositol (13**),^[2] 4-Azido-3-O-[2',6',6'-bisazido-2',3',4',6'-tetra-deoxy- α -D-hexopyranosyl]- (**14**), and 4-Azido-3-O-[2',a,6'-bisazido-2',3',4',6'-tetra-deoxy- β -D-hexopyranosyl]-1-N,2-O-carbonyl-6-O-methyl-1-N-methylamino-1,4,5-tri-deoxy-L-chiro-inositol (**15**):** **8** (78 mg, 0.37 mmol) and **10** (88 mg, 0.42 mmol) were treated with $\text{BF}_3 \cdot \text{OEt}_2$ (0.06 ml, 0.49 mmol) according to GP 1 (stirring for 4 h at 0°C); after chromatography [$\text{CH}_2\text{Cl}_2/\text{ethyl acetate}$, 2:1, R_f (**14**) = 0.59, R_f (**15**) = 0.49, R_f (**10**) = 0.19] **14** (83 mg), **10** (14 mg) and a mixture of **14/15** (22 mg) were secured. The latter was separated by preparative TLC ($\text{CH}_2\text{Cl}_2/$

ethyl acetate, 2:1) to give **14** (12 mg) and **15** (7 mg, total yield: 76%, $\alpha/\beta \approx 14:1$), both as colorless oils. **14**: $[\alpha]_{\text{D}}^{25} = -7.4$ ($c = 0.6$, CH_2Cl_2). – IR (KBr): $\tilde{\nu} = 2109 \text{ cm}^{-1}$ (N_3), 1762 (NCOO). – ^1H NMR: $\delta = 5.20$ (s, $1'\text{-H}$), 4.52 (dd, 2-H), 4.16 (dddd, $5'\text{-H}$), 3.82 (dd, 3-H), 3.75 (dd, 1-H), 3.69 (ddd, 4-H), 3.67 (ddd, 6-H), 3.57 (dd, $2'\text{-H}$), 3.42 (s, OCH_3), 3.38 (dd, $6'\text{-a-H}$), 3.18 (dd, $6'\text{-b-H}$), 2.82 (s, NCH_3), 2.19 (dddd, $5\alpha\text{-H}$), 2.14 (dddd, $3'\alpha\text{-H}$), 1.89 (dddd, $5\beta\text{-H}$), 1.74 (dddd, $3'\beta\text{-H}$), 1.70 (dddd, $4'\beta\text{-H}$), 1.50 (dddd, $3'\alpha\text{-H}$); $J_{1,2} = J_{2,3} = 7.2$, $J_{3,4} = 9.9$, $J_{4,5\beta} = 10.5$, $J_{4,5\alpha} = 14.5$, $J_{5\alpha,6} = J_{5\beta,6} = J_{1,6} = 3.0$, $J_{2',3'\alpha} = J_{2',3'\beta} = J_{3'\alpha,4'\alpha} = J_{3'\beta,4'\alpha} = J_{3'\beta,4'\beta} = J_{4'\alpha,5'} = 3.5$, $J_{3'\alpha,3'\beta} = J_{3'\alpha,4'\beta} = J_{4'\alpha,4'\beta} = 13.5$, $J_{4'\alpha,5'} = 3.5$, $J_{4'\beta,5'} = 11.5$, $J_{5',6'\text{a}} = 6.7$, $J_{5',6'\text{b}} = 4.0$, $J_{6'\text{a},6'\text{b}} = 12.9$ Hz. – ^{13}C NMR: $\delta = 158.0$ (C=O), 96.7 (C-1'), 78.3 (C-2), 78.0 (C-3), 74.0 (C-6), 68.7 (C-5'), 61.0 (C-1), 57.1 (OCH_3), 57.0 (C-2'), 56.6 (C-4), 54.8 (C-6'), 30.5 (NCH_3), 28.6 (C-5), 22.7 (C-4'), 22.2 (C-3'). – MS (ESI); m/z (%) = 883 (34) [$2 \text{M} + \text{K}$] $^+$, 867 (54) [$2 \text{M} + \text{Na}$] $^+$, 461 (63) [$\text{M} + \text{K}$] $^+$, 445 (100) [$\text{M} + \text{Na}$] $^+$, 340 (42). – $\text{C}_{15}\text{H}_{22}\text{N}_{10}\text{O}_5$ (422.4). **15**: $[\alpha]_{\text{D}}^{25} = -101.8$ ($c = 0.1$, CH_2Cl_2). – IR (KBr): $\tilde{\nu} = 2109 \text{ cm}^{-1}$ (N_3), 1769 (NCOO). – ^1H NMR: $\delta = 4.87$ (d, $1'\text{-H}$), 4.82 (dd, 2-H), 3.84 (ddd, 4-H), 3.78 (dd, 3-H), 3.78–3.70 (m, 1-, 6-, $5'\text{-H}$), 3.62 (ddd, $2'\text{-H}$), 3.44 (dd, $6'\text{-a-H}$), 3.40 (s, OCH_3), 3.23 (dd, $6'\text{-b-H}$), 2.82 (s, NCH_3), 2.11 (dddd, $5\alpha\text{-H}$), 2.04 (dddd, $3'\beta\text{-H}$), 1.77 (dddd, $5\beta\text{-H}$), 1.65 (dddd, $3'\alpha\text{-H}$), 1.59 (dddd, $4'\beta\text{-H}$), 1.40 (dddd, $4'\alpha\text{-H}$); $J_{1,2} = 5.9$, $J_{2,3} = 7.5$, $J_{3,4} = 9.0$, $J_{4,5\alpha} = 4.0$, $J_{4,5\beta} = 11.0$, $J_{5\alpha,5\beta} = 14.0$, $J_{5\alpha,6} = 5.0$, $J_{5\beta,6} = 3.0$, $J_{1',2'} = 1.6$, $J_{2',3'\alpha} = 4.5$, $J_{2',3'\beta} = 2.5$, $J_{3'\alpha,3'\beta} = 13.5$, $J_{3'\alpha,4'\alpha} = 3.5$, $J_{3'\alpha,4'\beta} = 11.3$, $J_{3'\beta,4'\alpha} = 4.5$, $J_{4'\beta,5'} = 13.5$, $J_{4'\beta,5'} = 13.5$, $J_{5',6'\text{a}} = 6.7$, $J_{5',6'\text{b}} = 4.0$, $J_{6'\text{a},6'\text{b}} = 12.9$ Hz. – MS (ESI); m/z (%) = 883 (36) [$2 \text{M} + \text{K}$] $^+$, 867 (58) [$2 \text{M} + \text{Na}$] $^+$, 461 (69) [$\text{M} + \text{K}$] $^+$, 445 (100) [$\text{M} + \text{Na}$] $^+$, 340 (34).

4-Azido-3-O-[2'-a-amino-6'-{trifluoroacetyl}[(1R)-phenylethyl]]amino-2',3',4',6'-tetra-deoxy- α -D-hexopyranosyl]-1-N,2-O-carbonyl-1,4,5-tri-deoxy-6-O-methyl-1-methylamino-L-chiro-inositol (16**):** A solution of **12** (15 mg, 0.022 mmol) in 3% methanolic NaOH solution (3 ml) and water (3 ml) was stirred until total conversion [75 min, TLC control, $\text{CHCl}_3/\text{methanol}$, 10:1, R_f (**12**) = 0.72, R_f (**16**) = 0.15]; the reaction was quenched with pH 7 buffer, the methanol removed in vacuo and the remaining aqueous phase extracted with CH_2Cl_2 . After drying (MgSO_4) and concentration in vacuo **16** (12 mg, 95%) was obtained as colorless oil. $[\alpha]_{\text{D}}^{25} = +25.0$ ($c = 0.1$, CHCl_3). – IR (KBr): $\tilde{\nu} = 2107 \text{ cm}^{-1}$ (N_3), 1768 (NCOO), 1686 ($6'\text{-NR}^*\text{COCF}_3$). – ^1H NMR: $\delta = 7.30$ (m, 5 H), 5.26 (q, $1''\text{-H}$), 5.19 (d, $1'\text{-H}$), 4.54 (dd, 2-H), 4.12 (m, $5''\text{-H}$), 3.77–3.61 (m, 1-, 3-, 4-, 6-H), 3.40 (s, OCH_3), 3.26 (dd, $6'\text{-a-H}$), 2.82 (s, NCH_3), 2.82 (m, $2'\text{-H}$), 2.60 (dd, $6'\text{-b-H}$), 2.18 (ddd, $5\alpha\text{-H}$), 1.70 (d, $2''\text{-H}$), 1.70–1.50, 1.40–1.20 (m, $5\beta\text{-}$, $3'\text{-H}$, $4'\text{-H}_2$); $J_{1',2'} = 3.5$, $J_{5',6'\text{a}} = 8.3$, $J_{6'\text{a},6'\text{b}} = 14.9$, $J_{1'',2''} = 7.0$, $J_{1,2} = J_{2,3} = 7.0$ Hz. – MS (FAB); m/z (%): 593 (2) [$\text{M} + \text{Na}$] $^+$, 571 (30) [$\text{M} + \text{H}$] $^+$, 329 (96) [$\text{C}_{16}\text{H}_{20}\text{F}_3\text{N}_2\text{O}_2$] $^+$, 225 (28) [$\text{C}_9\text{H}_{13}\text{N}_4\text{O}_3$] $^+$, 105 (100) [R^*] $^+$.

4-Azido-3-O-[2'-a-benzoyloxycarbonylamino-6'-{trifluoroacetyl}[(1R)-phenylethyl]]amino-2',3',4',6'-tetra-deoxy- α -D-hexopyranosyl]-1,4,5-tri-deoxy-6-O-methyl-1-(benzyloxycarbonyl)methylamino-L-chiro-inositol (17b**):** A solution of **12** (50 mg, 0.075 mmol) in 3% methanolic NaOH (10 ml) and water (6 ml) was refluxed for 4 h (TLC). The methanol was removed in vacuo; after extraction with CH_2Cl_2 , drying (MgSO_4) and concentration in vacuo crude **17a** was left. To a solution of the latter in DMF, *Z*-*O*-suc (45 mg, 0.18 mmol) was added and the reaction mixture was stirred at room temp. for 20 h. The solvent was removed in vacuo and the remaining residue filtered through silica gel ($\text{CH}_2\text{Cl}_2/\text{acetone}$, 20:1, $R_f = 0.22$) to yield **17b** (54 mg, 89%) as colorless oil. $[\alpha]_{\text{D}}^{25} = +101.1$ ($c = 0.1$, CHCl_3). – IR (KBr): $\tilde{\nu} = 3423 \text{ cm}^{-1}$ (OH), 3357 (NH),

2106 (N₃), 1684 (NHCOO), 1512 (NHCOO). – ¹H NMR: δ = 7.30 (m, 10 H), 5.55 (br. s, NH), 5.30 (q, 1''-H), 5.12–4.82 [m, 1'-H, 2CH₂, (Z)], 4.20–3.60 (m, 1-, 2-, 3-, 4-, 6-, 2'-H), 3.36 (s, OCH₃), 3.20 (d, 6'a-H), 2.98 (s, NCH₃), 2.68 (dd, 6'b-H), 2.42 (d, 5a-H), 1.70 (d, 2''-H), 1.90–1.50/1.10 (m, 4 H/1 H, 5β-H, 3', 4'-H₂). – ¹³C NMR: δ = 157.7 (C=O), 157.3 (C=O), 138.3–127.2 (12 C), 116.8 (q, COCF₃), 99.2 (C-1'), 77.2 (C-2)*, 76.3 (C-3)*, 74.1 (C-1), 69.9 (C-6), 67.3 (C-5'), 66.7, 64.7 [2 CH₂ (Z)], 59.7 (OCH₃)*, 59.5 (C-1'')*, 56.1 (C-4), 25.5 (C-5), 24.4 (C-4')*, 24.3 (C-3')*, 18.0 (C-2''); J_{C,F} = 287.8 Hz. – MS (FAB); m/z (%): 836 (6) [M + Na]⁺, 814 (24) [M + H]⁺, 813 (54) [M]⁺, 463 (15) [C₂₄H₂₆F₃N₂O₄]⁺, 333 (12) [C₁₆H₂₁N₄O₄]⁺, 195 (10) [C₁₆H₂₁N₄O₄ – Z, – 3 H]⁺, 105 (100) [R*]⁺.

4-Azido-3-O-[2'a-amino-6'-[(1R)-phenylethyl]amino-2',3',4',6'-tetra-deoxy-a-D-hexopyranosyl]-1,4,5-trideoxy-6-O-methyl-1-methylamino-L-chiro-inositol (18a): A solution of **12** (15 mg, 0.022 mmol) in 6 ml 3% methanolic NaOH (6 ml) and water (3 ml) was refluxed for 40 h (TLC). Methanol was removed in vacuo, the residue diluted with water and extracted with CH₂Cl₂. The organic phase was dried (MgSO₄) and concentrated in vacuo, **18a** (9 mg, 91%) was isolated as colorless oil. [α]_D²⁵ = +29.3 (c = 0.1, CHCl₃). – IR (KBr): ν̄ = 3338 cm⁻¹ (NH, OH), 2103 (N₃). – ¹H NMR: δ = 7.30 (m, 5 H), 5.10 (d, 1'-H), 4.08 (m, 5'-H), 3.89 (dd, 2-H), 3.78 (q, 1''-H), 3.67 (dd, 3-H), 3.55 (ddd, 6-H), 3.44 (ddd, 4-H), 3.39 (s, OCH₃), 2.97 (dd, 1-H), 2.82 (m, 2'-H), 2.58 (dd, 6'a-H), 2.46 (dd, 6'b-H), 2.38 (s, NCH₃), 2.10 (ddd, 5a-H), 1.98 (ddd, 5β-H), 1.75–1.20 (m, 3', 4'-H₂), 1.35 (d, 2''-H); J_{1',2'} = 3.5, J_{1,2} = 4.0, J_{2,3} = J_{3,4} = 9.6, J_{1,6} = J_{5a,6} = J_{5β,6} = 3.2 Hz. – ¹³C NMR: δ = 128.4 (C_m), 126.8 (C_o), 126.7 (C_p), 101.7 (C-1'), 83.2 (C-2)*, 77.3 (C-3)*, 75.6 (C-6), 67.7 (C-5'), 62.6 (C-1), 59.1 (OCH₃)*, 58.2 (C-4)*, 56.9 (C-1'')*, 52.0 (C-6'), 50.0 (C-2'), 35.2 (NCH₃), 29.1 (C-5'), 28.7 (C-4')*, 28.4 (C-3)*, 24.5 (C-2''). – MS (FAB); m/z (%): 461 (5) [M + Na]⁺, 449 (30) [M + H]⁺, 233 (18) [C₁₈H₂₁N₂O]⁺, 215 (8) [C₈H₁₅N₄O₄]⁺, 105 (67) [R*]⁺.

4-Azido-3-O-[2'a-benzyloxycarbonylamino-6'-{benzyloxy-carbonyl[(1R)-phenylethyl]}amino-2',3',4',6'-tetra-deoxy-a-D-hexopyranosyl]-1,4,5-trideoxy-6-O-methyl-1-(benzyloxy-carbonyl)methylamino-L-chiro-inositol (18b): To a solution of **18a** (15 mg, 0.03 mmol) in anhydrous DMF, Z-O-suc (27 mg, 0.11 mmol) was added and the reaction mixture was stirred at room temp. for 24 h. The solvent was removed in vacuo and the remaining residue chromatographed on silica gel (CH₂Cl₂/acetone, 20:1, R_f = 0.16) to yield **18b** (26 mg, 92%) as colorless oil. [α]_D²⁵ = +71.2 (c = 0.2, CHCl₃). – IR (KBr): ν̄ = 3422 cm⁻¹ (OH, NH), 2104 (N₃), 1710 (NCOO), 1686 (NHCOO), 1561 (NHCOO). – ¹H NMR: δ = 7.30 (m, 15 H), 5.45 (br. s, NH), 5.25 (m, 1''-H), 5.28–4.80 [m, 1'-H, 2 CH₂ (Z)], 4.10–3.65 (m, 1-, 2-, 3-, 4-, 6-, 2'-H), 3.34 (s, OCH₃), 3.12 (m, 6'a-H), 2.98 (s, NCH₃), 2.80 (dd, 6'b-H), 2.30 (m, 5a-H), 1.56 (d, 2''-H), 1.80–1.40/1.15 (m, 4 H/1 H, 5β-H, 3', 4'-H₂). – MS (FAB); m/z (%): 873 (3) [M + Na]⁺, 851 (30) [M + H]⁺, 717 (11) [M – Z, + 2 H]⁺, 501 (76) [C₃₀H₃₃N₂O₅]⁺, 397 (46) [C₃₀H₃₃N₂O₅ – R*, + H]⁺, 366 (8) [C₃₀H₃₃N₂O₅ – Z]⁺, 353 (37) [C₃₀H₃₃N₂O₅ – NHZ, + 2 H]⁺, 350 (18) [C₁₆H₂₁N₄O₅ + H]⁺, 333 (66) [C₁₆H₂₁N₄O₄]⁺, 315 (14) [C₁₆H₂₁N₄O₄ – H₂O]⁺, 302 (8) [C₁₆H₂₁N₄O₄ – OCH₃]⁺, 263 (12) [C₃₀H₃₃N₂O₅ – Z, – R*, + 2 H]⁺, 198 (10) [C₁₆H₂₁N₄O₄ – Z]⁺, 105 (100) [R*]⁺. – C₄₆H₅₄O₁₀N₆ (851.0).

4-Azido-3-O-[2'a-amino-6'-[(1R)-phenylethyl]amino-2',3',4',6'-tetra-deoxy-a-D-hexopyranosyl]-1-N,2-O-carbonyl-1,4,5-trideoxy-6-O-methyl-1-methylamino-L-chiro-inositol (19a): To a solution of **12** (58 mg, 0.087 mmol) in ethanol NaBH₄ (30 mg, 0.79 mmol) was added. After stirring for 22 h at room temp. [TLC, CHCl₃/meth-

anol, 10:1, R_f (**12**) = 0.72, R_f (**19a**) = 0.05], the solvent was removed in vacuo, the residue dissolved in water, extracted with CH₂Cl₂, dried (MgSO₄), and concentrated in vacuo, **19a** (36 mg, 87%) was isolated as colorless oil. [α]_D²⁵ = +28.4 (c = 0.1, CHCl₃). – IR (KBr): ν̄ = 3359 cm⁻¹ (NH), 2105 (N₃), 1763 (NCOO). – ¹H NMR: δ = 7.30 (m, 5 H), 5.12 (d, 1'-H), 4.56 (dd, 2-H), 3.92 (m, 5'-H), 3.87 (dd, 3-H), 3.81 (dd, 1-H), 3.77 (ddd, 4-H), 3.76 (m, 1''-H), 3.68 (m, 6-H), 3.40 (s, OCH₃), 2.84 (s, NCH₃), 2.79 (m, 2'-H), 2.54 (dd, 6'a-H), 2.48 (dd, 6'b-H), 2.14 (ddd, 5a-H), 1.74–1.43 (m, 5β-H, 3', 4'-H₂), 1.32 (d, 2''-H); J_{1',2'} = 3.2, J_{5',6'a} = 3.8, J_{5',6'b} = 7.0, J_{6'a,6'b} = 12.3, J_{1,2} = J_{2,3} = 6.7, J_{3,4} = 9.4, J_{4,5a} = J_{5a,6} = 4.8, J_{5a,5β} = 14.2 Hz. – ¹³C NMR: δ = 158.1 (C=O), 128.4 (C_m), 126.7 (C_o), 126.7 (C_p), 99.0 (C-1'), 77.9 (C-2)*, 77.2 (C-3)*, 74.3 (C-6), 67.8 (C-5'), 61.0 (C-1), 57.8 (OCH₃)*, 57.0 (C-4)*, 57.0 (C-1'')*, 51.8 (C-6'), 50.4 (C-2'), 30.4 (NCH₃), 28.5 (C-5'), 28.4 (C-4'), 27.8 (C-3'), 24.6 (C-2''). – MS (FAB); m/z (%): 475 (100) [M + H]⁺, 307 (10) [M – NHR*, – NH₂, – OCH₃]⁺, 249 (4) [C₁₄H₂₁N₂O₂]⁺, 233 (26) [C₁₄H₂₁N₂O]⁺, 129 (7) [C₁₄H₂₁N₂O – R*, + H]⁺, 105 (19) [R*]⁺.

4-Azido-3-O-[2'a-benzyloxycarbonylamino-6'-{benzyloxy-carbonyl[(1R)-phenylethyl]}amino-2',3',4',6'-tetra-deoxy-a-D-hexopyranosyl]-1-N,2-O-carbonyl-1,4,5-trideoxy-6-O-methyl-1-methylamino-L-chiro-inositol (19b): To a mixture of **19a** (36 mg, 0.076 mmol) in acetone (5 ml) and water (5 ml) sodium hydrogen carbonate (50 mg, 0.6 mmol) and Z chloride (26 μl, 0.184 mmol) were added. After stirring for 2 h at room temp. acetone was removed in vacuo, the aqueous phase diluted and extracted with CH₂Cl₂; drying (MgSO₄), concentration in vacuo, and chromatography on silica gel (ethyl acetate/cyclohexane, 2:1, R_f = 0.26) gave **19b** (53 mg, 94%) as colorless oil. [α]_D²⁵ = +34.6 (c = 0.2, CHCl₃). – IR (KBr): ν̄ = 3334 cm⁻¹ (NH), 2105 (N₃), 1768 (NCOO), 1698 (NHCOO), 1520 (NHCOO). – ¹H NMR: δ = 7.30 (m, 10 H), 5.51 (br. s, NH), 5.28 (br. s, 1''-H), 5.11 [br. s, 2 CH₂ (Z)], 4.84 (d, 1'-H), 4.41 (dd, 2-H), 4.09 (m, 5'-H), 3.81–3.58 (m, 2', 1-, 3-, 4-, 6-H), 3.39 (s, OCH₃), 3.20 (m, 6'a-H), 2.82 (m, 6'b-H), 2.80 (s, NCH₃), 2.10 (m, 5a-H), 1.78 (m, 5β-H), 1.60 (d, 2''-H), 1.70–1.48/1.22 (m, 3 H/1 H, 3', 4'-H₂). – ¹³C NMR: δ = 157.9, 155.6 (C=O), 136.8–127.2 (12 C), 95.1 (C-1'), 77.2 (C-2)*, 76.9 (C-3)*, 73.9 (C-6), 67.3 (C-5'), 67.2, 66.9 [CH₂ (Z)], 60.9 (C-1), 57.1 (OCH₃)*, 56.7 (C-1'')*, 54.8 (C-4)*, 54.7 (C-2')*, 49.4, 49.3 (C-6')*, 30.5 (NCH₃), 28.0 (C-5), 27.8 (C-4'), 24.6 (C-3'), 17.8 (C-2''). – MS (FAB); m/z (%): 766 (5) [M + Na]⁺, 744 (27) [M + H]⁺, 640 (19) [M – R*, + 2 H]⁺, 607 (9) [M – Z, – H]⁺, 502 (58), 502 (18) [M – R*, – Z, – H; or C₃₀H₃₃N₂O₅ + H]⁺, 397 (43) [C₃₀H₃₃N₂O₅ – R*, + H]⁺, 263 (9) [C₃₀H₃₃N₂O₅ – R*, – Z, + 2 H]⁺, 105 (100) [R*]⁺.

4-Azido-3-O-[2'a-benzyloxycarbonylamino-6'-{benzyloxy-carbonyl[(1R)-phenylethyl]}amino-2',3',4',6'-tetra-deoxy-a-D-erythro-hexopyranosyl]-1,4,5-trideoxy-6-O-methyl-1-methylamino-L-chiro-inositol (20): A mixture of **19b** (48 mg, 0.065 mmol) and Ba(OH)₂ · 8 H₂O (102 mg, 0.323 mmol) in dioxane/water (30 ml/15 ml) was refluxed for 8 h. The solvent was removed in vacuo and the residue digested with CH₂Cl₂ (5 × 10 ml); the combined organic phases were dried (MgSO₄), concentrated in vacuo, and chromatographed on silica gel [CHCl₃/methanol, 10:1, 1% NEt₃, R_f (**19b**) = 0.76, R_f (**20**) = 0.29], **20** (41 mg, 88%) was isolated as colorless oil. [α]_D²⁵ = +86.3 (c = 0.1, CHCl₃). – IR (KBr): ν̄ = 3336 cm⁻¹ (OH, NH), 2104 (N₃), 1697 (NHCOO), 1526 (NHCOO). – ¹H NMR: δ = 7.30 (m, 10 H), 5.25–5.05 [m, 1'-H, 1''-H, 2 CH₂ (Z)], 4.15 (m, 5'-H), 3.90–3.50 (m, 2', 2-, 3-, 4-, 6-H), 3.48 (s, OCH₃), 3.18 (m, 6'a-H), 2.91 (m, 6'b-H), 2.76 (m, 1-H), 2.32 (s, NCH₃), 2.00 (m, 5a-H), 1.77 (m, 5β-H), 1.70–1.40 (m, 3', 4'-H₂), 1.60 (d, 2''-H). – ¹³C NMR: δ = 156.7, 155.9 (C=O), 128.5–127.2 (10 C), 96.9,

96.7 (C-1'), 77.2 (C-2)*, 76.8 (C-3)*, 74.6 (C-6)*, 67.3 (C-5'), 66.7, 65.1 [2 CH₂, (Z)], 62.8 (C-1), 56.8 (OCH₃)*, 55.0 (C-4, C-1'')*, 49.9, 49.3 (C-6')*, 48.6, 48.5 (C-2')*, 29.7 (NCH₃), 28.7 (C-5)*, 28.0 (C-4')*, 24.6 (C-3'), 17.9 (C-2''). – MS (FAB); *m/z* (%): 729 (5) [M + Na]⁺, 717 (100) [M + H]⁺, 674 (2) [M – N₃]⁺, 609 (3) [M – R*, + 2H]⁺, 501 (9) [C₃₀H₃₃N₂O₅]⁺, 460 (3) [M – NRZ*, – 2 H]⁺, 353 (10) [C₃₀H₃₃N₂O₅ – NHZ, + 2 H]⁺, 397 (6) [C₃₀H₃₃N₂O₅ – R*, + H]⁺, 245 (4) [C₃₀H₃₃N₂O₅ – NRZ*, – 2 H]⁺, 199 (4) [C₁₈H₁₅N₂O₂]⁺, 105 (24) [R*]⁺.

4-Azido-3-O-[2'-a-benzyloxycarbonylamino-6'-{benzyloxycarbonyl[(1R)-phenylethyl]}amino-2',3',4',6'-tetra-deoxy-α-D-hexopyranosyl]-1,4,5-trideoxy-6-O-methyl-1-(benzyloxycarbonylglycyl)methylamino-L-chiro-inositol (21): **20** (30 mg, 0.042 mmol) was treated according to GP 2 [Z-gly-O-suc (15 mg, 0.05 mmol), 26 h, 60°C] to provide after twofold chromatography (CH₂Cl₂/ethyl acetate, 1:1, R_f = 0.37) **21** (31 mg, 81%) as colorless oil. – IR (KBr): $\tilde{\nu}$ = 3411 cm^{−1} (OH), 2103 (N₃), 1701 (NHCOO), 1638 (NHCO), 1509 (NHCO). – ¹H NMR: δ = 7.30 (m, 15 H), 5.70 (br. s, NH), 5.30–4.80 [m, 1'-H, 1''-H, 3 CH₂ (Z)], 4.52 (d, NH), 4.10–3.50 [m, 1-, 2-, 3-, 4-, 6-, 2'-, 5'-H, CH₂ (Gly)], 3.32 (s, OCH₃), 3.14 (dd, 6'a-H), 2.97 (s, NCH₃), 2.81 (dd, 6'b-H), 2.35 (m, 5β-H), 1.95–1.45 (m, 5α-H, 3'-H₂, 4'a-H), 1.52 (d, 2''-H), 1.15 (dddd, 4'β-H). – ¹³C NMR: δ = 169.0 (C=O, gly), 156.5, 156.3 (C=O, carbamate), 128.6–127.5 (15 C), 94.7 (C-1'), 80.7 (C-2)*, 76.6 (C-3)*, 74.1 (C-6), 69.3 (C-5'), 67.3 (CH₂, Z), 66.8 (CH₂, Z), 60.2 (C-1), 55.8 (OCH₃)*, 54.9 (C-4)*, 54.5 (C-1'')*, 50.1 (C-6'), 49.4 (C-2'), 43.1 (CH₂), 28.3 (NCH₃), 25.4 (C-5), 22.8 (C-3'), 15.1 (C-2''). – MS (FAB); *m/z* (%): 909 (38) [M + H]⁺, 804 (2) [M – R*, + H]⁺, 774 (3) [M – R*, – N(CH₃)COCH₂NH₂, – H]⁺, 502 (3) [M – 3 Z, + H], 501 (9) [C₃₀H₃₃N₂O₅]⁺, 460 (4) [M – 3 Z, – N₃, – H]⁺, 397 (5) [C₃₀H₃₃N₂O₅ – R*, + H]⁺, 390 (36) [C₁₈H₂₄N₅O₆]⁺, 365 (3) [C₃₀H₃₃N₂O₅ – NHZ, + 2 H]⁺, 105 (22) [R*]⁺.

4-Amino-3-O-(2'-a-amino-6'-amino-2',3',4',6'-tetra-deoxy-α-D-hexopyranosyl)-1,4,5-trideoxy-6-O-methyl-1-(glycyl)methylamino-L-chiro-inositol (1): **21** (20 mg, 0.022 mmol) was treated according to GP 3 (28 h) to give **1** (11 mg, 95%) as solid tetrahydrochloride salt.^[1]

4-Azido-3-O-(2'-a-amino-6'-azido-2',3',4',6'-tetra-deoxy-α-D-hexopyranosyl)-1-N,2-O-carbonyl-1,4,5-trideoxy-6-O-methyl-1-methylamino-L-chiro-inositol (22). – *Alternative 1:* A solution of **13** (15 mg, 0.030 mmol), 3% methanolic NaOH solution (3 ml), and water (3 ml) was stirred at room temp. for 45 min [total conversion, TLC, CHCl₃/methanol, 10:1, R_f (**13**) = 0.59, R_f (**22**) = 0.24]. The reaction mixture was quenched with pH 7 buffer, the methanol removed in vacuo, and the aqueous residue extracted with CH₂Cl₂. After drying (MgSO₄) and concentration in vacuo, **22** (11 mg, 93%) was isolated as colorless oil. – *Alternative 2:* A solution of **13** (15 mg, 0.030 mmol) in ethanol was treated with NaBH₄ (5 mg, 0.13 mmol); after 3 h stirring at room temp., the reaction was complete (TLC). The solution was concentrated in vacuo, the residue dissolved in water and extracted with CH₂Cl₂. After drying of the organic phase (MgSO₄) and concentration in vacuo, **22** (12 mg, quant.) was isolated as colorless oil. – IR (KBr): $\tilde{\nu}$ = 2106 cm^{−1} (N₃), 1755 (NCOO). – ¹H NMR: δ = 5.18 (d, 1'-H), 4.56 (dd, 2-H), 4.05 (m, 5'-H), 3.82 (dd, 3-H), 3.78–3.64 (m, 1-, 4-, 6-, 2'-H), 3.42 (s, OCH₃), 3.30 (dd, 6'a-H), 3.21 (dd, 6'b-H), 2.81 (s, NCH₃), 2.32 (ddd, 5α-H), 1.90–1.50 (m, 5β-H, 3'-, 4'-H₂); J_{1,2'} = 3.5, J_{1,2} = J_{2,3} = 7.5, J_{3,4} = 9.4, J_{5',6'a} = 6.4, J_{5',6'b} = 4.6, J_{6'a,6'b} = 12.6 Hz. – MS (CI, isobutane, 200 eV); *m/z* (%): 397 (13) [M + H]⁺, 379 (15) [M – NH₂, – H]⁺, 243 (100) [C₉H₁₃N₄O₄ + 2 H]⁺, 225 (21) [C₉H₁₃N₄O₃]⁺, 155 (32) [C₆H₁₁N₄O]⁺. – C₁₅H₂₄N₈O₅ (396.4).

4-Azido-3-O-(2'β,6'-bisazido-2',3',4',6'-tetra-deoxy-α-D-hexopyranosyl)-6-O-methyl-1-N-methylamino-1,4,5-trideoxy-L-chiro-inositol Hydrochloride (23): A solution of **14** (34 mg, 0.077 mmol) and NaOH (188 mg, 3.3 mmol) in methanol/water 1:1 (8 ml) was refluxed for 2 h. The methanol was removed in vacuo, the residue diluted with water and extracted with CH₂Cl₂. The organic phase was concentrated to 5 ml and extracted with 0.01 N HCl (5 ml). The aqueous phase was evaporated in vacuo to yield pure **23** (30 mg, 94%) as colorless solid. [α]_D²⁵ = +100.7 (c = 0.20, H₂O). – IR (KBr): $\tilde{\nu}$ = 3406 cm^{−1} (OH), 2109 (N₃). – ¹H NMR (D₂O/CH₃CN): δ = 4.89 (s, 1'-H), 4.28 (dd, 2-H), 4.15 (dd, 3-H), 3.99 (ddd, 4-H), 3.96 (m, 5'-H), 3.67 (dd, 6-H), 3.62 (dd, 2'-H), 3.31 (s, OCH₃), 3.27 (d, 6'a-H), 3.26 (d, 6'b-H), 3.18 (dd, 1-H), 2.62 (s, NCH₃), 2.32 (dt, 5α-H), 1.95 (dddd, 3'α-H), 1.81–1.67 (m, 3'β-, 5β-H), 1.60 (dddd, 4'β-H), 1.36 (m, 4'a-H); J_{1,2} = J_{2,3} = J_{3,4} = J_{4,5α} = J_{4,5β} = 3.5, J_{1,6} = J_{5α,6} = 10.5, J_{5α,5β} = 13.5, J_{5β,6} = 4.0, J_{1',2'} < 1.0, J_{2',3'α} = J_{3'α,4'α} = J_{3'β,4'β} = 4.0, J_{2',3'β} = 2.0, J_{3'α,3'β} = J_{3'α,4'β} = J_{4'α,4'β} = J_{4'β,5'} = 13.5, J_{5',6'a} = 4.5, J_{5',6'b} = 6.0, J_{6'a,6'b} = 5.0 Hz. – ¹³C NMR (D₂O/CH₃CN): δ = 98.5 (C-1'), 75.1 (C-2)*, 72.1 (C-3)*, 70.2 (C-6)*, 65.6 (C-5'), 61.3 (C-1), 58.4 (OCH₃), 57.4 (C-2'), 57.0 (C-4), 54.6 (C-6'), 30.7 (NCH₃), 28.8 (C-5), 22.4 (C-4'), 21.7 (C-3'). – MS (ESI); *m/z* (%) = 419 (2) [M + Na]⁺, 397 (100) [M + H]⁺.

4-Azido-3-O-(2'β,6'-bisazido-2',3',4',6'-tetra-deoxy-α-D-hexopyranosyl)-1-N-(N-benzyloxycarbonylglycyl)-6-O-methyl-1-N-methylamino-1,4,5-trideoxy-L-chiro-inositol (24): Treatment of **23** (30 mg, 0.73 mmol) according to GP 2 (Z-gly-O-suc, 16 h, 50°C) gave after twofold chromatography (CH₂Cl₂/ethyl acetate, 2:1, R_f = 0.12) **24** (30 mg, 68%) as colorless oil. [α]_D²⁵ = +51.8 (c = 0.10, CH₂Cl₂). – IR (KBr): $\tilde{\nu}$ = 3410 cm^{−1} (OH), 2109 (N₃), 1725 (NHCOO). – ¹H NMR: δ = 7.40–7.25 (m, 5 H), 5.79 (br. s, NH), 5.12 (s, CH₂, Gly), 4.89 (s, 1'-H), 4.45 (dd, 1-H), 4.14–4.05 (m, 2-, 3-, 6-H), 4.00–3.88 (m, 5'-H, CH₂, Z), 3.66 (dd, 2'-H), 3.36 (dd, 6'a-H), 3.36 (s, OCH₃), 3.16 (dd, 6'b-H), 3.16 (m, 4-H), 3.05 (s, NCH₃), 2.44 (ddd, 5α-H), 2.05 (dddd, 3'α-H), 1.93–1.82 (m, 5β-, 3'β-H), 1.69 (dddd, 4'β-H), 1.43 (dddd, 4'a-H); J_{1,2} = 2.5, J_{1,6} = 11.0, J_{4,5α} = J_{5α,6} = 4.0, J_{5α,5β} = 13.5, J_{1',2'} < 1.0, J_{2',3'β} = J_{3'β,4'α} = 2.5, J_{2',3'α} = J_{3'α,4'α} = 4.0, J_{3'α,3'β} = J_{3'α,4'β} = J_{4'α,4'β} = 13.0, J_{4'α,5'} = 5.5, J_{5',6'a} = 8.0, J_{5',6'b} = 3.0, J_{6'a,6'b} = 13.0 Hz. – ¹³C NMR: δ = 169.3 (C=O, gly), 156.3 (C=O, carbamate), 136.5 (C_s), 128.5–128.0 (5 C), 97.7 (C-1'), 75.6 (C-2)*, 73.0 (C-3)*, 69.8 (C-6)*, 69.5 (C-5')*, 66.9 [CH₂ (Z)], 59.9 (C-1), 57.8 (C-2'), 56.7 (OCH₃), 56.0 (C-4), 54.8 (C-6'), 43.3 (CH₂, gly), 32.3 (NCH₃), 30.3 (C-5), 22.6 (C-4'), 22.3 (C-3'). – MS (ESI); *m/z* (%) = 626 (43) [M + K]⁺, 610 (100) [M + Na]⁺, 588 (9) [M + H]⁺. – C₂₄H₃₃N₁₁O₇ (587.6).

4-Amino-3-O-(2'β,6'-diamino-2',3',4',6'-tetra-deoxy-α-D-hexopyranosyl)-1-N-glycyl-6-O-methyl-1-N-methylamino-1,4,5-trideoxy-L-chiro-inositol (2): **24** (19 mg, 0.03 mmol) was treated according to GP 3 (2 h) to provide **2** (16 mg, quant.) as solid tetrahydrochloride.^[1]

4-Azido-3-O-[2'β-iodo-6'-{trifluoroacetyl[(1R)-phenylethyl]}amino-2',3',4',6'-tetra-deoxy-α-D-hexopyranosyl]- (27) and 4-Azido-3-O-[2'α-iodo-6'-{trifluoroacetyl[(1R)-phenylethyl]}amino-2',3',4',6'-tetra-deoxy-β-D-hexopyranosyl]-1-N,2-O-carbonyl-1,4,5-trideoxy-6-O-methyl-1-methylamino-L-chiro-inositol (32), 2'-Iodo-2',3',4',6'-tetra-deoxy-6'-{trifluoroacetyl[(1R)-phenylethyl]}amino-D-hex-1'-enopyranose (34): To a mixture of **9** (134 mg, 0.43 mmol), **10** (104 mg, 0.43 mmol) and molecular sieve (3 Å, 500 mg) in anhydrous CH₂Cl₂/CH₃CN (2:1) **26** (300 mg, 0.66 mmol) was added. After stirring for 16 h at room temp., the reaction was complete [TLC, cyclohexane/ethyl acetate, 1:1, R_f (**27**) = 0.25, R_f (**32**) =

0.30]. The sieve was filtered off and the solution washed with saturated Na_2SO_3 , then with saturated CuSO_4 solution. The organic phase was dried (MgSO_4), concentrated in vacuo, and the residue chromatographed on silica gel [CH_2Cl_2 /ethyl acetate, 15:1, R_f (**27**) = 0.31, R_f (**32**) = 0.17] to yield **27** (210 mg, 72%) and **32** (47 mg, 16%) as colorless crystals. Conversion in CH_2Cl_2 led (1 h, room temp.) to **27** (182 mg, 62%) and **32** (77 mg, 26%), in CH_3CN [24 h, after 12 h second addition of **26** (150 mg, 0.33 mmol), room temp.] to **27** (175 mg, 60%), **32** (23 mg, 8%) and **34** (39 mg, 21%) as by-product.

27: M.p. 63°C. – $[\alpha]_{\text{D}}^{25} = +12.3$ ($c = 0.1$, CHCl_3). – IR (KBr): $\tilde{\nu} = 2100 \text{ cm}^{-1}$ (N_3), 1762 (NCOO), 1675 (NR^*COCF_3). – ^1H NMR: $\delta = 7.31$ (m, 5 H), 5.51 (s, 1'-H), 5.27 (q, 1''-H), 4.50 (dd, 2-H), 4.31 (m, 5'-H), 4.24 (m, 2'-H), 3.73 (m, 3-H), 3.70–3.60 (m, 1-, 4-, 6-H), 3.42 (s, OCH_3), 3.28 (dd, 6'-a-H), 2.82 (s, NCH_3), 2.75 (dd, 6'-b-H), 2.29 (m, 5 α -H), 2.20 (m, 5 β -H), 1.87 (m, 4'-H), 1.71 (d, 2''-H), 1.68–1.35 (m, 4'-H, 3'-H₂); $J_{1,2'} < 1$, $J_{5',6'a} = 1.6$, $J_{5',6'b} = 6.2$, $J_{6'a,6'b} = 14.2$, $J_{1,2} = J_{2,3} = 7.2$, $J_{1,6} = 3.5$, $J_{4,5\alpha} = 4.5$, $J_{4,5\beta} = 10.5$, $J_{5\alpha,6} = 4.5$, $J_{5\beta,6} = 3.7$, $J_{5\alpha,5\beta} = 14.4$ Hz. – ^{13}C NMR: $\delta = 158.1$ (C=O), 138.9 (C_8), 129.0 (C_m), 128.1 (C_o), 127.3 (C_p), 117.0 (q, COCF_3), 98.4 (C-1'), 78.4 (C-2), 77.4 (C-3), 73.9 (C-6), 66.0 (C-5'), 61.2 (C-1), 57.1 (C-4), 56.6 (OCH_3), 55.5 (C-1''), 49.7 (C-6'), 30.5 (NCH_3), 28.6 (C-5), 27.5 (C-4'), 27.4 (C-3'), 24.8 (C-2'), 18.0 (C-2''); $J_{\text{C,F}} = 287.7$ Hz. – MS (CI, NH_3 , 170 eV); m/z (%): 699 (14) $[\text{M} + \text{NH}_3, + \text{H}]^+$, 595 (6) $[\text{M} + \text{NH}_3, + 2 \text{H} - \text{R}^*]^+$, 578 (12) $[\text{M} + \text{NH}_3, - \text{R}^*, - \text{CH}_3]^+$, 440 (38) $[\text{C}_{16}\text{H}_{18}\text{F}_3\text{INO}_2]^+$, 336 (12) $[\text{C}_{16}\text{H}_{18}\text{F}_3\text{INO}_2 - \text{R}^*, + \text{H}]^+$, 314 (84) $[\text{C}_{16}\text{H}_{18}\text{F}_3\text{INO}_2 - \text{I}, + \text{H}]^+$, 260 (100) $[\text{C}_9\text{H}_{13}\text{N}_4\text{O}_4 + \text{NH}_3, + 2 \text{H}]^+$, 243 (24) $[\text{C}_9\text{H}_{13}\text{N}_4\text{O}_4 + 2 \text{H}]^+$. – $\text{C}_{25}\text{H}_{31}\text{F}_3\text{IN}_5\text{O}_6$ (681.5): calcd. C 44.07, H 4.59, N 10.28; found C 44.24, H 4.56, N 10.11.

32: ^1H NMR: $\delta = 7.45$ –7.29 (m, 5 H), 5.31 (q, 1''-H), 4.65 (d, 1'-H), 4.63 (dd, 2-H), 3.87 (ddd, 4-H), 3.79 (dd, 3-H), 3.74 (ddd, 2'-H), 3.66 (dd, 1-H), 3.62 (ddd, 6-H), 3.52 (m, 5'-H), 3.40 (s, OCH_3), 3.12 (d, 6'-a-, 6'-b-H), 2.88 (s, NCH_3), 2.39 (dddd, 3'- β -H), 2.06 (m, 5 α -H), 2.00 (dddd, 3'- α -H), 1.77 (ddd, 5 β -H), 1.70 (d, 2''-H), 1.30 (m, 4'- α -H), 1.17 (dddd, 4'- β -H); $J_{1,2} = 7.5$, $J_{2,3} = 5.5$, $J_{3,4} = J_{4,5\alpha} = J_{4,5\beta} = J_{5\alpha,6} = J_{5\beta,6} = 3.5$, $J_{1,6} = 7.0$, $J_{1,2'} = 8.5$, $J_{2',3'\alpha} = J_{3'\alpha,3'\beta} = J_{3'\alpha,4'\beta} = J_{4'\beta,5} = 13.5$, $J_{2',3'\beta} = J_{5',6'a} = J_{5',6'b} = 5.0$, $J_{3',4'\alpha} = 4.5$, $J_{3',4'\beta} = J_{3'\beta,4'\beta} = 3.5$ Hz. – ^{13}C NMR: $\delta = 158.0$ (C=O), 157.6 (C=O), 138.1 (C_8), 128.9 (C_m), 128.4 (C_o), 127.6 (C_p), 104.0 (C-1'), 116.8 (q, COCF_3), 79.2 (C-2), 76.7 (C-3), 76.4 (C-6), 74.7 (C-5'), 60.3 (C-1), 56.9 (OCH_3), 56.8 (C-4), 55.4 (C-1''), 48.3 (C-6'), 36.2 (C-5')*, 30.5 (NCH_3), 32.1 (C-2')*, 27.6 (C-4)*, 27.5 (C-3)*, 17.9 (C-2''); $J_{\text{C,F}} = 287.9$ Hz. – MS (ESI); m/z (%): 720 (56) $[\text{M} + \text{K}]^+$, 704 (25) $[\text{M} + \text{Na}]^+$, 682 (100) $[\text{M} + \text{H}]^+$, 578 (7), 444 (18).

34: ^1H NMR: $\delta = 7.38$ (m, 5 H), 6.62 (d, 1'-H), 5.30 (q, 1''-H), 4.18 (m, 5'-H), 3.30 (dd, 6'-a-H), 2.80 (dd, 6'-b-H), 2.47 (m, 3'- α -H), 2.25 (m, 3'- β -H), 1.81 (dddd, 4'- α -H), 1.69 (d, 2''-H), 1.59 (dddd, 4'- β -H); $J_{3'\alpha,4'\alpha} = J_{4'\alpha,3'\beta} = J_{4'\alpha,5} = 3.75$, $J_{3'\alpha,4'\beta} = J_{4'\beta,5} = 14.0$, $J_{4'\alpha,4'\beta} = 14.0$, $J_{5',6'a} = 3.0$, $J_{5',6'b} = 9.0$, $J_{6'a,6'b} = 14.0$ Hz. – ^{13}C NMR: $\delta = 146.6$ (C-1'), 138.3 (C_8), 129.0 (C_m), 128.3 (C_o), 127.2 (C_p), 76.6 (C-5'), 55.4 (C-1''), 49.4 (C-6'), 32.1 (C-3')*, 28.3 (C-4'), 18.0 (C-2''). – MS (CI, isobutane, 70 eV); m/z (%): 440 (91) $[\text{M} + \text{H}]^+$, 336 (18) $[\text{M} - \text{R}^*, + 2 \text{H}]^+$, 314 (100) $[\text{M} - \text{I}, + 2 \text{H}]^+$, 210 (99) $[\text{M} - \text{R}^*, - \text{I}, + 3 \text{H}]^+$, 105 (32) $[\text{R}^*]^+$.

4-Azido-3-O-{2'- β -iodo-6'-[(1*R*)-phenylethyl]amino-2',3',4',6'-tetra-deoxy- α -D-hexopyranosyl}-1-N,2-O-carbonyl-1,4,5-trideoxy-6-O-methyl-1-methylamino-L-chiro-inositol (28**)**: A solution of **27** (100 mg, 0.15 mmol) in anhydrous ethanol (30 ml) was treated with NaBH_4 (17 mg, 0.45 mmol) at room temp.; after stirring for 6 h, the reaction was complete [TLC control, CHCl_3 /methanol, 10:1, R_f

(**27**) = 0.74, R_f (**28**) = 0.5]. Excess of NaBH_4 was destroyed with acetic acid (pH = 7), the solvent removed in vacuo and the residue dissolved in water. Extraction with CH_2Cl_2 , drying (MgSO_4), concentration in vacuo, and filtration through silica gel (CHCl_3 /methanol, 10:1) provided **28** (77 mg, 87%) as colorless oil. $[\alpha]_{\text{D}}^{25} = +8.0$ ($c = 0.1$ CHCl_3). – IR (KBr): $\tilde{\nu} = 2106 \text{ cm}^{-1}$ (N_3), 1765 (NCOO). – ^1H NMR: $\delta = 7.32$ (m, 5 H), 5.44 (s, 1'-H), 4.50 (dd, 2-H), 4.29 (m, 2'-H), 4.09 (m, 5'-H), 3.85–3.60 (m, 1-, 3-, 4-, 6-, 1''-H, NH), 3.40 (s, OCH_3), 2.81 (s, NCH_3), 2.54 (m, 6'-a-, 6'-b-H), 2.18 (m, 5-H₂), 1.90/1.65 (m, 3 H/1 H, 4'-, 3'-H₂), 1.32 (d, 2''-H); $J_{1,2'} < 1$, $J_{1,2} = 7.3$, $J_{2,3} = 6.4$ Hz. – ^{13}C NMR: $\delta = 158.1$ (C=O), 128.8 (C_m), 126.8 (C_o), 126.7 (C_p), 99.2 (C-1'), 77.8 (C-2)*, 77.4 (C-3)*, 74.0 (C-6), 68.9 (C-5'), 60.9 (C-1), 57.7 (OCH_3)*, 57.1 (C-1'')*, 56.8 (C-4)*, 51.7 (C-6'), 30.4 (NCH_3), 28.5 (C-5'), 28.0 (C-4')*, 27.4 (C-3')*, 24.7 (C-2'), 24.5 (C-2''). – MS (FAB); m/z (%): 586 (86) $[\text{M} + \text{H}]^+$, 482 (6) $[\text{M} + 2 \text{H} - \text{R}^*]^+$, 458 (6) $[\text{M} - \text{I}]^+$, 307 (22) $[\text{M} - \text{R}^*, - \text{OCH}_3, - \text{CH}_3, - \text{I}]^+$, 330 (8) $[\text{C}_{14}\text{H}_{19}\text{INO} + \text{H} - \text{CH}_3]^+$, 240 (29) $[\text{C}_9\text{H}_{13}\text{N}_4\text{O}_4 - \text{H}, \text{C}_{14}\text{H}_{19}\text{INO} - \text{R}^*, + \text{H}]^+$, 105 (100) $[\text{R}^*]^+$.

4-Azido-3-O-{2'- β -iodo-6'-[(1*R*)-phenylethyl]amino-2',3',4',6'-tetra-deoxy- α -D-hexopyranosyl}-1-N,2-O-carbonyl-1,4,5-trideoxy-6-O-methyl-1-methylamino-L-chiro-inositol (29**)**, **4-Azido-3-O-{2'- β -iodo-6'-[dimethyl, (1*R*)-phenylethyl]amino-2',3',4',6'-tetra-deoxy- α -D-hexopyranosyl}-1-N,2-O-carbonyl-1,4,5-trideoxy-6-O-methyl-1-methylamino-L-chiro-inositol iodide (**35**)**: A solution of **28** (50 mg, 0.085 mmol) in anhydrous acetonitrile was treated with K_2CO_3 (70 mg, 0.5 mmol) and CH_3I (106 μl , 1.70 mmol). After stirring for 2 h at room temp., excess of CH_3I was destroyed with 2 N NaOH. The acetonitrile was removed in vacuo, the remaining solution diluted and extracted with CH_2Cl_2 . After drying (MgSO_4) and concentration in vacuo, chromatography on silica gel [ethyl acetate, R_f (**29**) = 0.45, R_f (**28**) = 0.25] gave **29** (37 mg, 72%) and **28** (11 mg, 22%) as colorless oils. After 24 h reaction time, **29** (24 mg, 47%) and **35** (29 mg, 46%) were isolated chromatographically [CHCl_3 /methanol, 5:1, R_f (**29**) = 0.40, R_f (**35**) = 0.21], the latter as yellowish solid.

29: $[\alpha]_{\text{D}}^{25} = +13.9$ ($c = 0.1$, CHCl_3). – IR (KBr): $\tilde{\nu} = 2105 \text{ cm}^{-1}$ (N_3), 1774 (NCOO). – ^1H NMR: $\delta = 7.30$ (m, 5 H), 5.41 (s, 1'-H), 4.50 (dd, 2-H), 4.27 (m, 2'-H), 4.09 (m, 5'-H), 3.80 (dd, 3-H), 3.76–3.60 (m, 1-, 4-, 6-, 1''-H), 3.39 (s, OCH_3), 2.80 (s, NCH_3), 2.60 (dd, 6'-a-H), 2.48 (dd, 6'-b-H), 2.22 (s, NCH_3), 2.10 (dddd, 5 α -H), 1.90 (dddd, 5 β -H), 1.71 (m, 4'-H₂), 1.60 (m, 3'-H₂), 1.47 (d, 2''-H); $J_{1,2'} < 1$, $J_{5',6'a} = 6.2$, $J_{5',6'b} = 5.9$, $J_{6'a,6'b} = 13.4$, $J_{1,2} = 7.8$, $J_{2,3} = 6.4$, $J_{3,4} = 9.6$, $J_{4,5\alpha} = 4.5$, $J_{5\alpha,6} = 4.5$, $J_{4,5\beta} = 7.0$, $J_{5\alpha,5\beta} = 14.2$ Hz. – ^{13}C NMR: $\delta = 128.1$ (C_m), 127.9 (C_o), 126.7 (C_p), 99.3 (C-1'), 78.0 (C-2)*, 77.4 (C-3)*, 74.2 (C-6)*, 68.9 (C-5'), 63.0 (C-1''), 61.0 (C-1), 58.4 (OCH_3)*, 57.1 (C-6')*, 56.9 (C-4)*, 39.5 (NCH_3), 30.5 (NCH_3), 28.5 (C-5'), 28.4 (C-4')*, 28.4 (C-3)*, 25.7 (C-2''). – MS (FAB); m/z (%): 600 (42) $[\text{M}]^+$, 496 (6) $[\text{M} - \text{R}^*, + \text{H}]^+$, 307 (44) $[\text{M} - \text{R}^*\text{N}(\text{CH}_3), - \text{OCH}_3, - \text{HI}]^+$, 246 (10) $[\text{C}_{15}\text{H}_{21}\text{INO}_2 - \text{HI}]^+$, 243 (12) $[\text{C}_9\text{H}_{13}\text{N}_4\text{O}_4 + 2 \text{H}]^+$, 232 (12) $[\text{C}_{15}\text{H}_{21}\text{INO} - \text{HI}, + 2 \text{H}]^+$, 184 (10) $[\text{C}_9\text{H}_{13}\text{N}_4\text{O}_3 - \text{N}_3, + \text{H}]^+$, 179 (12) $[\text{C}_9\text{H}_{13}\text{N}_4\text{O}_3 - \text{CH}_3, - \text{OCH}_3]^+$, 136 (100) $[\text{RN}(\text{CH}_3)_2]^+$, 105 (100) $[\text{R}^*]^+$.

35: M.p. 169°C. – IR (KBr): $\tilde{\nu} = 2103 \text{ cm}^{-1}$ (N_3), 1760 (NCOO). – ^1H NMR: $\delta = 7.65$ (m, 2 H), 7.49 (m, 3 H), 5.42 (s, 1'-H), 4.72 (q, 1''-H), 4.58 (dd, 2-H), 4.39 (m, 2'-H), 3.85 (dd, 1-H), 3.79–3.70 (m, 3-, 4-, 6-H), 3.55 [s, NCH_3 (q)], 3.43 (s, OCH_3), 3.38 (dd, 6'-a-H), 3.11 [s, NCH_3 (q)], 2.95 (dd, 6'-b-H), 2.81 (s, NCH_3), 2.25 (m, 5 α -H), 3'- α -H), 2.07 (dddd, 3'- β -H), 1.90 (dddd, 1 H, 4'- α -H), 1.83 (d, 2''-H), 1.71 (dddd, 4'- β -H), 1.60 (ddd, 5 β -H); $J_{1,2'} < 1$, $J_{2',3'\alpha} = J_{2',3'\beta} = J_{3',4'\alpha} = J_{3',4'\beta} = J_{3'\beta,4'\alpha} = J_{4',5} =$

3.8, $J_{3'a,3'\beta} = J_{4'a,4'\beta} = 13.0$, $J_{3'a,4'\beta} = J_{4'a,5'} = 12.3$, $J_{1,2} = J_{2,3} = 7.2$, $J_{4,5a} = J_{5a,6} = 3.8$, $J_{4,5\beta} = 10.2$, $J_{5a,5\beta} = 13.0$ Hz. — ^{13}C NMR: $\delta = 158.3$ (C=O), 144.8 (C_s), 132.6 (C_m), 139.9 (C_o), 129.5 (C_p), 102.6 (C-1'), 83.0 (C-2), 76.6 (C-3), 74.7 (C-5')*, 73.4 (C-6)*, 66.7 (C-6')*, 65.4 (C-1'')*, 60.5 (C-1), 58.0 (C-4)*, 57.5 (OCH_3)*, 48.1 (NCH_3), 47.5 (NCH_3), 30.4 (NCH_3), 28.5 (C-5), 26.8 (C-4'), 26.3 (C-3'), 24.7 (C-2'), 15.5 (C-8'). — MS (CI, isobutane, 200 eV); m/z (%): 614 (4) $[\text{M}]^+$, 599 (2) $[\text{M} - \text{CH}_3, + \text{H}]^+$, 552 (7) $[\text{M} - 2 \times \text{CH}_3, - \text{OCH}_3, - \text{H}]^+$, 510 (100) $[\text{M} - \text{R}^*, + \text{H}]^+$, 382 (41) $[\text{M} - \text{R}^*, - \text{I}]^+$, 268 (14) $[\text{C}_{16}\text{H}_{24}\text{INO} - \text{R}^*]^+$, 243 (3) $[\text{C}_9\text{H}_{13}\text{N}_4\text{O}_4 + 2 \text{H}]^+$, 105 (71) $[\text{R}^*]^+$, 140 (7) $[\text{C}_{16}\text{H}_{24}\text{INO}, - \text{R}^*, - \text{HI}]^+$.

4-Azido-3-O-{6'-[methyl, (1R)-phenylethyl]amino-2',3',4',6'-tetra-deoxy- α -D-hex-2'-eno-pyranosyl}-1,4,5-trideoxy-6-O-methyl-1-methylamino-L-chiro-inositol (30): A solution of **29** (30 mg, 0.05 mmol) in 3% methanolic NaOH (5 ml) and water (5 ml) was refluxed for 2 h (TLC, CHCl_3 /methanol, 10:1, $R_f = 0.24$). The solution was concentrated to half its volume and diluted with water. After extraction with CH_2Cl_2 and drying (MgSO_4), concentration in vacuo gave **30** (21 mg, 94%) as colorless oil. $[\alpha]_{\text{D}}^{25} = +8.1$ ($c = 0.1$, CHCl_3). — IR (KBr): $\tilde{\nu} = 3433 \text{ cm}^{-1}$ (OH), 2107 (N_3). — ^1H NMR: $\delta = 7.30$ (m, 5 H), 6.00 (m, 2'-H), 5.77 (m, 3'-H), 5.36 (br. s, 1'-H), 4.23 (dd, 2-H), 4.12 (m, 5'-H), 3.90 (dd, 3-H), 3.90 (ddd, 4-H), 3.62 (q, 1''-H), 3.54 (ddd, 6-H), 3.40 (s, OCH_3), 2.97 (dd, 1-H), 2.65 (dd, 6'a-H), 2.35 (s, NCH_3), 2.27 (s, NCH_3), 2.22 (dd, 6'b-H), 2.05 (m, 5a-H), 1.91 (m, 5 β -H), 1.85–1.70 (m, 4'-H₂), 1.40 (d, 2''-H); $J_{2',3'} = 10.1$, $J_{5',6'a} = 8.8$, $J_{6'a,6'b} = 13.1$, $J_{1,2} = 3.7$, $J_{2,3} = J_{3,4} = 9.2$, $J_{4,5a} = 4.5$, $J_{4,5\beta} = 9.2$, $J_{5a,6} = J_{5\beta,6} = J_{1,6} = 3.8$ Hz. — ^{13}C NMR: $\delta = 142.2$ (C_s), 128.8 (C_m), 128.1 (C_o , C_p), 127.1 (C-2'), 125.7 (C-3'), 90.5 (C-1'), 80.2 (C-2)*, 75.5 (C-3)*, 67.7 (C-6), 65.1 (C-5'), 64.2 (C-1''), 63.7 (C-1), 57.7 (OCH_3)*, 56.8 (C-6')*, 56.7 (C-4)*, 40.7 (NCH_3), 35.1 (NCH_3), 28.8 (C-5), 28.3 (C-4'), 18.7 (C-2''). — MS (FAB); m/z (%): 446 (46) $[\text{M}]^+$, 307 (8) $[\text{M} - \text{R}^*, - \text{H}_2\text{O}, - \text{CH}_3, - \text{H}]^+$, 230 (10) $[\text{C}_{15}\text{H}_{20}\text{NO}]^+$, 165 (18) $[\text{C}_8\text{H}_{15}\text{N}_4\text{O}_2 - \text{H}_2\text{O}, - \text{CH}_3, - \text{H}]^+$, 155 (20) $[\text{C}_8\text{H}_{15}\text{N}_4\text{O}_2 - \text{N}_3, - 2 \text{H}]^+$, 136 (100) $[\text{R}^*(\text{NCH}_3)_3]^+$, 105 (98) $[\text{R}^*]^+$.

4-Azido-3-O-{6'-[methyl, (1R)-phenylethyl]amino-2',3',4',6'-tetra-deoxy- α -D-hex-2'-eno-pyranosyl}-1,4,5-trideoxy-6-O-methyl-1-(benzyloxycarbonylglycyl)methylamino-L-chiro-inositol (31): **30** (20 mg, 0.045 mmol) was treated according to GP 2 [Z -gly-O-suc (21 mg, 0.07 mmol), DMF, 20 h, 70°C] to yield after twofold chromatography (CHCl_3 /methanol, 10:1, $R_f = 0.36$) **31** (22 mg, 77%) as colorless oil. — IR (KBr): $\tilde{\nu} = 2103 \text{ cm}^{-1}$ (N_3), 1719 (NHCOO), 1655 (NHCO), 1560 (NHCO). — ^1H NMR: $\delta = 7.30$ (m, 10 H), 6.00 (m, 2'-H), 5.80 (m, 3'-H), 5.72 (m, 1'-H), 5.60 [s, CH_2 , (Z)], 4.45 (dd, 1-H), 4.20–3.85 [m, 5'-, 2-, 3-, 6-H, CH_2 , (Gly)], 3.69–3.62 (m, 4-, 1''-H), 3.34 (s, OCH_3), 2.98 (s, NCH_3), 2.60 (dd, 6'a-H), 2.32 (s, NCH_3), 1.95 (m, 5 β -H), 1.85 (m, 5a-H), 1.48 (d, 2''-H), 1.32–1.20 (m, 4'-H₂). — ^{13}C NMR: $\delta = 129.2$ – 127.8 (10 C), 127.0 (C-2'), 125.3 (C-3'), 95.3 (C-1'), 77.2 (C-2)*, 76.9 (C-3)*, 75.5 (C-6)*, 69.9 (C-5'), 66.8 [CH_2 , (Z)], 63.9 (C-1''), 60.1 (C-1), 58.1 (OCH_3)*, 58.0 (C-6')*, 55.8 (C-4)*, 43.4 [CH_2 , (Gly)], 40.5 (NCH_3), 30.2 (NCH_3), 29.7 (C-5), 28.6 (C-4'), 18.0 (C-2''). — MS (FAB); m/z (%): 637 (14) $[\text{M}]^+$, 400 (18) $[\text{M} - \text{R}^*, - \text{Z}, - 2 \text{H}]^+$, 390 (8) $[\text{C}_{18}\text{H}_{24}\text{N}_5\text{O}_5]^+$, 358 (20) $[\text{C}_{18}\text{H}_{24}\text{N}_5\text{O}_5 - \text{OCH}_3, - \text{H}]^+$, 343 (6) $[\text{C}_{18}\text{H}_{24}\text{N}_5\text{O}_5 - \text{OCH}_3, - \text{H}_2\text{O}]^+$, 326 (5) $[\text{C}_{18}\text{H}_{24}\text{N}_5\text{O}_5 - \text{OCH}_3, - \text{CH}_3, - \text{H}_2\text{O}]^+$, 289 (18) $[\text{M} - \text{R}^*\text{N}(\text{CH}_3), - \text{Z-Gly-N}(\text{CH}_3), + 2 \text{H}]^+$, 230 (16) $[\text{C}_{15}\text{H}_{20}\text{NO}]^+$, 105 (96) $[\text{R}^*]^+$.

4-Amino-3-O-(6'-methylamino-2',3',4',6'-tetra-deoxy- α -D-hexopyranosyl)-1,4,5-trideoxy-6-O-methyl-1-(glycyl)methylamino-L-chiro-inositol (3): **31** (20 mg, 0.031 mmol) was treated according to GP 3 (9 h) to give **3** (13 mg, 89%, TLC: 2-propanol/water/25% NH_3 , 4:1:1, $R_f = 0.40$) as solid trishydrochloride. — IR (KBr): $\tilde{\nu} =$

1735 cm^{-1} (NHCO), 1655 (sec. NH_2^+), 1459 (prim. NH_3^+), 1038 (m, OH). — ^1H NMR (D_2O , CH_3CN): $\delta = 4.83$ (br. s, 1'-H), 4.68 (dd, 1-H), 4.25 (ddd, 6-H), 4.20 (m, 2-, 3-H), 4.10 (m, CH_2), 3.70 (m, 4-, 5'-H), 3.49 (s, OCH_3), 3.10 (s, NCH_3), 2.82 (m, 6'-H), 2.79 (s, NCH_3), 2.60 (ddd, 5 β -H), 2.10 (m, 5a-H), 1.80–1.50 (m, 2'-, 3'-, 4'-H₂); $J_{5',6'a} = 3.5$, $J_{5',6'b} = 6.5$, $J_{6'a,6'b} = 13.0$, $J_{1,2} = 3.0$, $J_{1,6} = 11.0$, $J_{4,5a} = 4.6$, $J_{4,5\beta} = J_{5\beta,6} = 4.6$, $J_{5a,5\beta} = 13.7$, $J_{5a,6} = 11$ Hz. — ^{13}C NMR (D_2O , CH_3CN): $\delta = 90.8$ (C-1'), 74.1 (C-3), 70.4 (C-6), 69.3 (C-2), 65.8 (C-5'), 56.3 (C-1), 55.6 (OCH_3), 51.4 (C-6'), 48.7 (C-4), 40.8 (CH_2), 33.4 (NCH_3), 31.4 (NCH_3), 28.9 (C-5), 27.3 (C-2'), 26.8 (C-4'), 21.9 (C-3'). — MS (FAB); m/z (%): 369 (24) $[\text{M} - 4 \text{H}]^+$, 335 (22) $[\text{M} - 4 \text{H}, - \text{NH}_2, - \text{H}_2\text{O}]^+$, 277 (100) $[\text{M} - 4 \text{H}, - \text{NH}_2, - \text{H}_2\text{O}, - \text{COCH}_2\text{NH}_2]^+$, 243 (75) $[\text{C}_{10}\text{H}_{20}\text{N}_3\text{O}_4 - 3 \text{H}]^+$, 185 (100) $[\text{C}_{10}\text{H}_{20}\text{N}_3\text{O}_4 - 3 \text{H}, - \text{COCH}_2\text{NH}_2]^+$, 128 (63) $[\text{C}_7\text{H}_{14}\text{NO}]^+$.

4-Azido-3-O-{2'β,6'-[(1R)-phenylethyl]amino-3',4',6'-trideoxy- α -D-hexopyranosyl}- (42), 4-Azido-3-O-{2'α,6'-[(1R)-phenylethyl]amino-3',4',6'-trideoxy- α -D-hexopyranosyl}- (43), and 4-Azido-3-O-{6'-[(1R)-phenylethyl]amino-2',3',4',6'-tetra-deoxy- α -D-hexopyranosyl}-1-N,2-O-carbonyl-1,4,5-trideoxy-6-O-methyl-1-methylamino-L-chiro-inositol (44): Through a solution of **27** (50 mg, 0.073 mmol) in benzene (30 ml) in the presence of Bu_3SnH (58 μl , 0.22 mmol) a continuous stream of oxygen was run (48 h at 50°C). The reaction mixture was concentrated in vacuo to 5 ml and diluted with methanol (30 ml). After addition of NaBH_4 (30 mg), the mixture was stirred for 4 h at room temp.; methanol was removed in vacuo, the residue dissolved in water and extracted with CH_2Cl_2 . After drying (MgSO_4), concentration in vacuo, and chromatography on silica gel [CHCl_3 /methanol, 10:1, R_f (**44**) = 0.43, R_f (**43**) = 0.2, R_f (**42**) = 0.15], the three components **44** (14 mg, 42%), **43** (3 mg, 8%), and **42** (13 mg, 37%) were isolated as colorless oils.

42: IR (KBr): $\tilde{\nu} = 3449 \text{ cm}^{-1}$ (OH), 2106 (N_3), 1763 (NCOO). — ^1H NMR: $\delta = 7.31$ (m, 5 H), 5.16 (s, 1'-H), 4.52 (dd, 2-H), 4.02 (m, 5'-H), 3.87–3.60 (m, 2'-, 1''-, 1-, 3-, 4-, 6-H), 3.42 (s, OCH_3), 2.82 (s, NCH_3), 2.50 (m, 6'a-, 6'b-H), 2.16 (dddd, 5a-H), 2.00 (m, 5 β -H), 1.78–1.40 (m, 3'-, 4'-H₂), 1.32 (d, 2''-H); $J_{1',2'} < 1$, $J_{1,2} = J_{2,3} = 7.2$, $J_{4,5a} = J_{5a,6} = 4.7$, $J_{5a,5\beta} = 15$ Hz. — ^{13}C NMR: $\delta = 128.4$ (C_m), 126.7 (C_p), 98.4 (C-1'), 77.9 (C-2)*, 77.2 (C-2'')*, 77.1 (C-3)*, 74.2 (C-6), 65.9 (C-5'), 61.0 (C-1), 57.8 (C-1'')*, 57.1 (C-4)*, 56.8 (OCH_3)*, 51.8 (C-6'), 30.4 (NCH_3), 29.7 (C-5), 28.5 (C-4')*, 24.7 (C-3')*, 22.4 (C-2''). — MS (FAB); m/z (%): 476 (40) $[\text{M}]^+$, 460 (7) $[\text{M} - \text{CH}_3, - \text{H}]^+$, 433 (8) $[\text{M} - \text{N}_3, + \text{H}]^+$, 372 (6) $[\text{M} - \text{R}^*, + \text{H}]^+$, 307 (12) $[\text{M} - \text{R}^*, - \text{OCH}_3, - \text{CH}_3, - \text{H}_2\text{O}]^+$, 234 (12) $[\text{C}_{14}\text{H}_{20}\text{NO}_2]^+$, 217 (8) $[\text{C}_{14}\text{H}_{20}\text{NO}_2 - \text{OH}]^+$, 179 (26) $[\text{C}_9\text{H}_{13}\text{N}_4\text{O}_3 - \text{OCH}_3 - \text{CH}_3]^+$, 105 (100) $[\text{R}^*]^+$.

43: IR (KBr): $\tilde{\nu} = 3448 \text{ cm}^{-1}$ (OH), 2106 (N_3), 1758 (NCOO). — ^1H NMR: $\delta = 7.32$ (m, 5 H), 5.30 (d, 1'-H), 4.60 (dd, 2-H), 3.97 (m, 5'-H), 3.88 (dd, 3-H), 3.82–3.60 (m, 2'-, 1-, 4-, 6-, 1''-H), 3.43 (s, OCH_3), 2.87 (s, NCH_3), 2.55 (dd, 6'a-H), 2.48 (dd, 6'b-H), 2.20 (ddd, 5a-H), 1.85–1.40 (m, 5 β -H, 3'-, 4'-H₂), 1.35 (d, 2''-H); $J_{1',2'} = 3.5$, $J_{5',6'a} = 3.5$, $J_{5',6'b} = 7.2$, $J_{6'a,6'b} = 12.3$, $J_{1,2} = J_{2,3} = 7.2$, $J_{2,3} = 9.4$, $J_{4,5a} = J_{5a,6} = 4.6$, $J_{5a,5\beta} = 14.2$ Hz. — MS (FAB); m/z (%): 476 (77) $[\text{M}]^+$, 460 (82) $[\text{M} - \text{CH}_3, - \text{H}]^+$, 372 (4) $[\text{M} - \text{R}^* + \text{H}]^+$, 329 (4) $[\text{M} - \text{R}^*, - \text{N}_3]^+$, 307 (24) $[\text{M} - \text{R}^*, - \text{OCH}_3, - \text{CH}_3, - \text{H}_2\text{O}]^+$, 242 (8) $[\text{C}_9\text{H}_{13}\text{N}_4\text{O}_4 + \text{H}]^+$, 234 (18) $[\text{C}_{14}\text{H}_{20}\text{NO}_2]^+$, 183 (16) $[\text{C}_9\text{H}_{13}\text{N}_4\text{O}_3 - \text{N}_3]^+$, 179 (46) $[\text{C}_9\text{H}_{13}\text{O}_3\text{N}_4 - \text{OCH}_3, - \text{CH}_3]^+$, 105 (100) $[\text{R}^*]^+$.

44: IR (KBr): $\tilde{\nu} = 2105 \text{ cm}^{-1}$ (N_3), 1769 (NCOO). — ^1H NMR: $\delta = 7.31$ (m, 5 H), 5.30 (br. s, 1'-H), 4.50 (dd, 2-H), 3.97 (m, 5'-H), 3.85–3.60 (m, 1-, 3-, 4-, 6-, 1''-H), 3.40 (s, OCH_3), 2.81 (s, NCH_3), 2.46 (m, 6'a-, 6'b-H), 2.10 (dddd, 5a-H), 1.82 (m, 5 β -H), 1.75–1.35 (m, 2'-, 3'-, 4'-H₂), 1.30 (d, 2''-H); $J_{1,2} = J_{2,3} = 6.7$,

$J_{4,5a} = J_{5a,6} = 4.3$, $J_{5a,5\beta} = 14.0$ Hz. – MS (FAB); m/z (%): 460 (100) $[M]^+$, 307 (12) $[M - R^*, -OCH_3, -CH_3, -2H]^+$, 234 (14) $[C_{14}H_{20}NO_2]^+$, 218 (16) $[C_{14}H_{20}NO]^+$, 183 (10) $[C_9H_{13}N_4O_3 - N_3]^+$, 179 (44) $[C_9H_{13}N_4O_3 - OCH_3, -CH_3]^+$, 105 (100) $[R]^+$.

4-Azido-3-O-[6'-{trifluoroacetyl[(1*R*)-phenylethyl]}amino-2' β -O-(2,2,6,6-tetramethylpiperidinyl)-3',4',6'-trideoxy- α -D-hexopyranosyl]- (36), 4-Azido-3-O-[6'-{trifluoroacetyl[(1*R*)-phenylethyl]}amino-2' α -O-(2°-2°,6°,6°-tetramethylpiperidinyl)-3',4',6'-trideoxy- α -D-hexopyranosyl]- (45), and 4-Azido-3-O-[6'-{trifluoroacetyl[(1*R*)-phenylethyl]}amino-2',3',4',6'-tetra-deoxy- α -D-hexopyranosyl]-1-*N*,2-*O*-carbonyl-1,4,5-trideoxy-6-*O*-methyl-1-methylamino-*L*-chiro-inositol (46): A solution of **27** (114 mg, 0.167 mmol), TEMPO (78 mg, 0.5 mmol), and Bu_3SnH (89 μ l, 0.335 mmol) in anhydrous benzene (50 ml) was refluxed for 4.5 h (total conversion, TLC). The solvent was removed in vacuo and the residue chromatographed on silica gel $[CH_2Cl_2/acetone, 10:1, R_f(27) = 0.62, R_f(45) = 0.72, R_f(46) = 0.65, R_f(36) = 0.49]$ to give **45** (5 mg, 4%), **46** (6 mg, 6%) and **36** (93 mg, 78%), **36** and **45** as colorless solids, **46** as colorless oil.

36: M.p. 63°C. – IR (KBr): $\tilde{\nu} = 2102\text{ cm}^{-1}$ (N_3), 1764 (NCOO), 1676 (NR*COCF₃). – ¹H NMR: $\delta = 7.32$ (m, 5 H), 5.53 (s, 1'-H), 5.25 (q, 1''-H), 4.52 (dd, 2-H), 4.20 (m, 5'-H), 3.80–3.60 (m, 1-, 3-, 4-, 6-, 2'-H), 3.41 (s, OCH₃), 3.28 (dd, 6'a-H), 2.85 (s, NCH₃), 2.66 (dd, 6'b-H), 2.10 (ddd, 5a-H), 1.90 (m, 5 β -H), 1.73 (d, 2''-H), 1.52 (s, 4CH₃), 1.65–1.15 (m, 3'-, 4'-, 3°-, 4°-, 5°-H₂); $J_{1',2'} < 1$, $J_{5',6'a} = 2.1$, $J_{5',6'b} = 8.9$, $J_{6'a,6'b} = 14.0$, $J_{1,2} = 7.3$, $J_{2,3} = 6.1$, $J_{4,5a} = J_{5a,6} = 4.3$, $J_{5a,5\beta} = 14.7$ Hz. – ¹³C NMR: $\delta = 158.1$ (C=O), 139.1 (C_s), 128.8 (C_m), 127.9 (C_o), 127.2 (C_p), 117.0 (q, COCF₃), 95.3 (C-1'), 78.1 (C-2)*, 77.4 (C-2')*, 75.7 (C-3)*, 74.3 (C-6)*, 65.2 (C-5'), 61.1 (C-1), 59.0 (C-2°, C-6°), 56.9 (OCH₃)*, 56.7 (C-4)*, 55.5 (C-1''), 49.9 (C-6'), 40.4 (C-3°, C-4°, C-5°), 30.5 (NCH₃), 28.1 (C-5), 23.5 (C-4')*, 23.1 (C-3')*, 18.0 (CH₃)*, 17.2 (C-2'')*; $J_{C,F} = 287.4$ Hz. – MS (FAB); m/z (%): 733 (20) $[M + Na]^+$, 711 (100) $[M]^+$, 485 (14) $[C_{25}H_{36}F_3N_2O_4]^+$, 469 (20) $[C_{25}H_{36}F_3N_2O_3]^+$, 450 (12) $[M - R^*, -C_9H_{18}NO]^+$, 422 (15) $[M - R^*N(COCF_3), -N_3, -OCH_3]^+$, 341 (50) $[M - R^*N(COCF_3), -C_9H_{18}NO, +2H]^+$, 329 (6) $[C_{25}H_{36}F_3N_2O_3 - C_9H_{18}NO]^+$, 307 (40) $[M - R^*N(COCF_3), -OCH_3, -C_9H_{18}NO, +H]^+$, 243 (17), $[C_9H_{13}N_4O_4 - 2H]^+$, 200 (22) $[C_9H_{13}N_4O_4 - N_3, +H]^+$, 196 (48) $[C_9H_{13}N_4O_4 - OCH_3, -CH_3, +H]^+$, 105 (100) $[R]^+$. – $C_{34}H_{49}F_3N_6O_7$ (710.8): calcd. C 57.45, H 6.95, N 11.82; found C 57.39, H 7.18, N 10.82.

45: M.p. 66–68°C. – $[\alpha]_D^{25} = +13.6$ ($c = 0.1$, $CHCl_3$). – IR (KBr): $\tilde{\nu} = 2107\text{ cm}^{-1}$ (N_3), 1771 (NCOO), 1686 (NR*COCF₃). – ¹H NMR: $\delta = 7.32$ (m, 5 H), 5.40 (d, 1'-H), 5.24 (m, 1''-H), 4.60 (dd, 2-H), 4.17 (m, 5'-H), 3.70–3.50 (m, 1-, 3-, 4-, 6-, 2'-H), 3.42 (s, OCH₃), 3.22 (ddd, 6a'-H), 2.88 (s, NCH₃), 2.59 (dd, 6'b-H), 2.08 (m, 5-H), 1.85 (dddd, 3' β -H), 1.70 (d, 2''-H), 1.50–1.00 (m, 3'-, 4'-, 3°-, 4°-, 5°-H₂, 4 CH₃); $J_{1',2'} = 3.5$, $J_{2',3'\beta} = J_{3'\beta,4'\beta} = 7.8$, $J_{3'a,3'\beta} = 16.3$, $J_{3'\beta,4'a} = 4.0$, $J_{5',6'a} = 1.3$, $J_{5',6'b} = 8.3$, $J_{6'a,6'b} = 14.0$, $J_{1,2} = J_{2,3} = 7.3$ Hz. – ¹³C NMR: $\delta = 138.9$ (C_s), 128.8 (C_m), 128.0 (C_o), 127.2 (C_p), 95.8 (C-1'), 79.6 (C-2)*, 78.0 (C-2')*, 75.9 (C-3)*, 74.6 (C-6)*, 65.6 (C-5'), 61.1 (C-1), 57.0 (OCH₃)*, 56.9 (C-4)*, 55.4 (C-1''), 49.3 (C-6'), 40.3 (C-3°, C-4°, C-5°), 30.5 (NCH₃), 28.8 (C-5), 28.1 (C-4'), 23.9 (C-3'), 18.0 (CH₃)*, 17.2 (C-2'')*. – MS (FAB); m/z (%): 711 (39) $[M]^+$, 554 (15) $[M - C_9H_{18}NO, -H]^+$, 469 (6) $[C_{25}H_{36}F_3N_2O_3]^+$, 450 (8) $[M - R^*, -C_9H_{18}NO]^+$, 422 (20) $[M - R^*N(COCF_3), -OCH_3, -N_3]^+$, 243 (8) $[C_9H_{13}N_4O_4 + 2H]^+$, 199 (8) $[C_9H_{13}N_4O_4 - N_3]^+$, 196 (21) $[C_9H_{13}N_4O_4 - OCH_3, -CH_3, +H]^+$, 105 (100) $[R]^+$. – $C_{34}H_{49}F_3N_6O_7$ (710.8): calcd. C 57.45, H 6.95, N 11.82; found C 57.15, H 6.89, N 11.50.

46: IR (KBr): $\tilde{\nu} = 2100\text{ cm}^{-1}$ (N_3), 1761 (NCOO), 1674 (NR*COCF₃). – ¹H NMR: $\delta = 7.32$ (m, 5 H), 5.40 (br. s, 1'-H), 5.23 (q, 1''-H), 4.52 (dd, 2-H), 4.20 (m, 5'-H), 3.70 (m, 1-, 3-, 4-, 6-H), 3.42 (s, OCH₃), 3.23 (dd, 6'a-H), 2.82 (s, NCH₃), 2.59 (dd, 6'b-H), 2.18 (ddd, 5a-H), 1.72 (d, 2''-H), 1.90–1.50 (m, 5 β -H, 2'-, 3'-, 4'-H₂); $J_{5',6'a} = 2.4$, $J_{5',6'b} = 8.9$, $J_{6'a,6'b} = 14.9$, $J_{1,2} = J_{2,3} = 7.3$, $J_{4,5\beta} = J_{5\beta,6} = 3.7$, $J_{4,5a} = J_{5a,6} = 4.5$, $J_{5a,5\beta} = 14.4$ Hz. – ¹³C NMR: $\delta = 158.2$ (C=O), 139.0 (C_s), 128.8 (C_m), 128.0 (C_o), 127.3 (C_p), 117.1 (q, COCF₃), 95.1 (C-1'), 78.7 (C-2)*, 76.1 (C-3)*, 74.2 (C-6)*, 65.7 (C-5'), 61.3 (C-1), 56.9 (OCH₃), 56.8 (C-4), 55.4 (C-1''), 50.1 (C-6'), 30.4 (NCH₃), 29.2 (C-5), 28.6 (C-2'), 17.9 (C-3', C-4')*, 17.4 (C-2'')*. – MS (EI); m/z (%): 555 (6) $[M]^+$, 450 (2) $[M - R^*]^+$, 313 (62) $[C_{16}H_{19}F_3NO_2 + H]^+$, 243 (96) $[C_9H_{13}N_4O_4 + 2H]^+$, 216 (21) $[C_{16}H_{19}F_3NO_2 - COCF_3 - H]^+$, 210 (28) $[C_{16}H_{19}F_3NO_2 - R^*, +H]^+$, 105 (100) $[R]^+$. – MS (NH₃, 170 eV); m/z (%): 573 (44) $[M + NH_4]^+$, 528 (6) $[M + NH_3, -CH_3, -OCH_3]^+$, 331 (10) $[C_{16}H_{19}F_3NO_2 + NH_3]^+$, 314 (100) $[C_{16}H_{19}F_3NO_2]^+$, 260 (44) $[C_9H_{13}N_4O_4 + NH_3, +2H]^+$, 243 (7) $[C_9H_{13}N_4O_4 + 2H]^+$.

4-Amino-3-O-[2' β ,6'-{trifluoroacetyl[(1*R*)-phenylethyl]}amino-3',4',6'-trideoxy- α -D-hexopyranosyl]- (37a) and 4-Amino-3-O-[6'-{trifluoroacetyl[(1*R*)-phenylethyl]}amino-2' β -O-(2°-2°,6°,6°-tetramethylpiperidinyl)-3',4',6'-trideoxy- α -D-hexopyranosyl]-1-*N*,2-*O*-carbonyl-1,4,5-trideoxy-6-*O*-methyl-1-methylamino-*L*-chiro-inositol (47): To a solution of **36** (85 mg, 0.12 mmol) in acetic acid (10 ml) was added zinc powder (150 mg). After stirring for 40 h at room temp., the zinc was removed by filtration, the filtrate was neutralized with saturated sodium hydrogen carbonate solution, and extracted with CH_2Cl_2 . After drying ($MgSO_4$), concentration in vacuo, and chromatography on silica gel ($CHCl_3$ /methanol, 10:1, $R_f = 0.22$), **37a** (55 mg, 84%) was obtained as colorless oil. If the reaction was quenched after 6 h, besides **37a** (26%) the precursor **47** (63%) was isolated.

37a: $[\alpha]_D^{25} = +17.2$. – ($c = 0.1$, $CHCl_3$). – IR (KBr): $\tilde{\nu} = 1765\text{ cm}^{-1}$ (NCOO), 1678 (NR*COCF₃). – ¹H NMR: $\delta = 7.48$ (m, 5 H), 5.26 (q, 1'-H), 5.18 (s, 1'-H), 4.43 (dd, 2-H), 4.32 (m, 5'-H), 3.72 (ddd, 1-H), 3.63 (m, 2'-, 6-H), 3.49 (dd, 3-H), 3.48 (s, OCH₃), 3.16 (dd, 6'a-H), 2.95 (ddd, 4-H), 2.83 (s, NCH₃), 2.70 (dd, 6'b-H), 2.12 (dddd, 5a-H), 1.92 (m, 5 β -H), 1.62 (d, 2''-H), 1.70–1.20 (m, 3'-, 4'-H₂); $J_{1',2'} < 1$, $J_{5',6'a} = 2.4$, $J_{5',6'b} = 9$, $J_{6'a,6'b} = 14$, $J_{1,2} = J_{2,3} = 7.3$, $J_{3,4} = 10$, $J_{4,5a} = 4.3$, $J_{4,5\beta} = 10.0$, $J_{5a,5\beta} = 14.6$, $J_{1,6} = 4.0$ Hz. – ¹³C NMR: $\delta = 138.6$ (C_s), 128.9 (C_m), 128.2 (C_o), 127.2 (C_p), 117.0 (q, COCF₃), 97.9 (C-1'), 80.4 (C-2)*, 78.6 (C-2')*, 74.5 (C-3)*, 65.6 (C-6), 64.1 (C-5'), 62.0 (C-1), 56.6 (C-1'')*, 55.7 (OCH₃)*, 49.6 (C-6'), 45.8 (C-4), 31.0 (NCH₃), 30.3 (C-5), 25.1 (C-4'), 22.6 (C-3'), 17.8 (C-2''). – MS (FAB); m/z (%): 568 (9) $[M + Na + H]^+$, 546 (51) $[M]^+$, 424 (9) $[M - R^*, -OH]^+$, 350 (8) $[M - R^*, -CO_2, -OCH_3, -NH_2]^+$, 330 (25) $[C_{16}H_{19}F_3NO_3]^+$, 226 (18) $[C_{16}H_{19}F_3NO_3 - R^*, +H]^+$, 217 (63) $[C_9H_{15}N_2O_4 + 2H]^+$, 199 (19) $[C_9H_{15}N_2O_3]^+$, 155 (25) $[C_9H_{15}N_2O_3 - CO_2]^+$, 105 (100) $[R]^+$.

47: $[\alpha]_D^{25} = +40.8$ ($c = 0.1$, $CHCl_3$). – IR (KBr): $\tilde{\nu} = 1768\text{ cm}^{-1}$ (NCOO), 1684 (NR*COCF₃). – ¹H NMR: $\delta = 7.30$ (m, 5 H), 5.54 (s, 1'-H), 5.27 (q, 1''-H), 4.45 (dd, 2-H), 4.31 (m, 5'-H), 3.72–3.58 (m, 2'-, 1-, 6-H), 3.40 (dd, 3-H), 3.38 (s, OCH₃), 3.20 (dd, 6'a-H), 2.95 (ddd, 4-H), 2.82 (s, NCH₃), 2.10 (m, 5a-H), 1.90 (m, 5 β -H), 1.70 (d, 2''-H), 1.80–1.20 (m, 3'-, 4'-H₂, 4 CH₃, 3'-, 4'-, 5''-H₂); $J_{1',2'} < 1$, $J_{5',6'a} = 2.7$, $J_{5',6'b} = 9.9$, $J_{6'a,6'b} = 14.2$, $J_{1,2} = J_{2,3} = 7.2$ Hz. – MS (FAB); m/z (%): 685 (36) $[M]^+$, 469 (4) $[C_{25}H_{36}F_3N_2O_3]^+$, 424 (6) $[M - R^*, -C_9H_{18}NO]^+$, 330 (10) $[C_{25}H_{36}F_3N_2O_3 - C_9H_{18}N, +H]^+$, 217 (8) $[C_9H_{15}N_2O_4 + 2H]^+$, 200 (28) $[C_9H_{15}N_2O_3 + H, C_9H_{15}N_2O_4 - NH_2, +H]^+$, 105 (100) $[R]^+$.

3-O-[2',6',6'-{Trifluoroacetyl}[(1*R*)-phenylethyl]amino-3',4',6'-trideoxy- α -D-hexopyranosyl]-1-N,2-O-carbonyl-1,4,5-trideoxy-6-O-methyl-4-(benzyloxycarbonylamino)-1-methylamino-L-chiro-inositol (37b): A solution of **37a** (50 mg, 0.09 mmol) and Z-O-suc (27 mg, 0.11 mmol) in DMF (20 ml) was stirred 14 h at room temp.; the solvent was removed in vacuo and the residue chromatographed on silica gel (CHCl₃/methanol, 10:1, *R_f* = 0.43) to provide **37b** (59 mg, 95%) as colorless oil. $[\alpha]_D^{25} = +29.3$ (*c* = 0.1, CHCl₃). – IR (KBr): $\tilde{\nu}$ = 3365 cm⁻¹ (OH), 1765 (NCOO), 1677 (NR*COCF₃). – ¹H NMR: δ = 7.32 (m, 10 H), 6.00 (d, NH), 5.22 (m, 1'-, 1''-H, CH₂), 5.01 [d, CH₂, (Z)], 4.52 (dd, 2-H), 4.32 (m, 5'-H), 4.04 (dddd, 4-H), 3.73 (dd, 1-H), 3.68 (ddd, 6-H), 3.57 (m, 2'-H), 3.46 (dd, 3-H), 3.39 (s, OCH₃), 3.07 (dd, 6'a-H), 2.82 (s, NCH₃), 2.66 (dd, 6'b-H), 2.70 (ddd, 5 α -H), 1.68 (d, 2''-H), 1.65–1.10 (m, 5 β -H, 4'-, 3'-H₂); *J*_{1',2'} < 1, *J*_{5',6'a} = 2.9, *J*_{5',6'b} = 10.2, *J*_{6'a,6'b} = 13.7, *J*_{1,2} = *J*_{2,3} = 7.2, *J*_{3,4} = *J*_{4,5 α} = 11, *J*_{4,5 α} = 3.5, *J*_{5 α ,5 β} = 13.4, *J*_{5 α ,6} = *J*_{5 β ,6} = 3.5, *J*_{1,6} = 3.2 Hz. – ¹³C NMR: δ = 158.3 (C=O), 156.5 (C=O), 138.3 (C_s), 129.3–127.2 (10 C), 117.3 (q, COCF₃), 96.5 (C-1'), 79.1 (C-2)*, 74.8 (C-2')*, 73.9 (C-3)*, 72.8 (C-6)*, 66.4 (CH₂), 65.3 (C-5'), 62.5 (C-4), 61.6 (C-1), 56.7 (OCH₃), 56.1 (C-1''), 49.5 (C-6'), 30.1 (NCH₃), 29.5 (C-5), 25.5 (C-4')*, 24.7 (C-3')*, 17.5 (C-2''); *J*_{C,F} = 287.9 Hz. – MS (FAB); *m/z* (%): 680 (16) [M + H]⁺, 589 (8) [M – C₇H₇]⁺, 529 (10) [M – NHZ, – H]⁺, 513 (18) [M – NHZ, – OH]⁺, 407 (18) [M – NHZ, – R*, – H₂O]⁺, 351 (100) [C₁₇H₂₁N₂O₆ + 2 H]⁺, 330 (100) [C₁₆H₁₉F₃NO₃]⁺, 260 (73) [C₁₇H₂₁N₂O₆ + 2 H, – C₇H₇]⁺, 226 (100) [C₁₆H₁₉F₃NO₃ – R* + H]⁺, 200 (100) [C₁₇H₂₁N₂O₆ – NHZ, + H]⁺, 105 (100) [R*]⁺.

3-O-[2',6',6'-[(1*R*)-Phenylethyl]amino-3',4',6'-trideoxy- α -D-threo-hexopyranosyl]-1-N,2-O-carbonyl-1,4,5-trideoxy-6-O-methyl-4-(benzyloxycarbonylamino)-1-(methylamino)-L-chiro-inositol (38): A solution of **37b** (60 mg, 0.088 mmol) in anhydrous ethanol (8 ml) was treated with NaBH₄ (10 mg, 0.26 mmol) at room temp.; after 4 h stirring at room temp., conversion was complete [TLC, CHCl₃/methanol, 10:1, *R_f* (**37b**) = 0.52, *R_f* (**38**) = 0.12]. The solvent was removed in vacuo, the residue dissolved in water and extracted with CH₂Cl₂. After drying (MgSO₄) and concentration in vacuo the crude product was filtered through silica gel (CHCl₃/methanol, 10:1) to yield **38** (44 mg, 86%) as colorless oil. $[\alpha]_D^{25} = +12.1$ (*c* = 0.2, CHCl₃). – ¹H NMR: δ = 7.28 (m, 10 H), 5.21 [d, CH₂, (Z)], 5.01 (br. s, 1'-H), 4.56 (dd, 2-H), 4.10 (m, 5'-H), 3.96 (m, 4-H), 3.80–3.70 (m, 1-, 6-H), 3.68–3.64 (m, 1'', 2'-H*), 3.52 (m, 3-H*), 3.40 (s, OCH₃), 2.80 (s, NCH₃), 2.38–2.12 (m, 6'a-, 6'b-, 5 α -H), 1.80–1.30 (m, 5 β -H, 3'-, 4'-H₂), 1.30 (d, 2''-H). – ¹³C NMR: δ = 158.6 (C=O), 156.7 [C=O, (Z)], 136.9 (C_s), 128.6–126.5 (10 C), 99.5 (C-1'), 79.3 (C-2)*, 77.3 (C-2')*, 73.8 (C-3)*, 66.6 (C-6), 65.8 (C-5'), 61.7 (C-1), 58.6 (C-1'')*, 56.4 (OCH₃)*, 50.8 (C-6'), 30.3 (NCH₃), 29.8 (C-5), 25.5 (C-3'), 23.3 (C-4')*, 22.5 (C-2''). – MS (FAB); *m/z* (%): 584 (100) [M]⁺, 306 (99) [C₁₇H₂₁N₂O₆ – CO₂, + H]⁺, 250 (8) [C₁₄H₂₀NO₃]⁺, 234 (29) [C₁₄H₂₀NO₂]⁺.

3-O-[2',6',6'-[(1*R*)-Phenylethyl]methylamino-3',4',6'-trideoxy- α -D-hexopyranosyl]-1-N,2-O-carbonyl-1,4,5-trideoxy-6-O-methyl-4-(benzyloxycarbonylamino)-1-(methylamino)-L-chiro-inositol (39): A solution of **38** (25 mg, 0.043 mmol) in acetonitrile (10 ml) was treated with K₂CO₃ (300 mg, 2.17 mmol) and CH₃I (53 μ l, 0.857 mmol). After stirring for 2 h at room temp., the excess of CH₃I was destroyed with 2 N NaOH (5 ml). The reaction mixture was concentrated to its half, diluted with water and extracted with CH₂Cl₂. After drying (MgSO₄), concentration in vacuo and chromatography on silica gel [CHCl₃/methanol, 10:1, *R_f* (**38**) = 0.12, *R_f* (**39**) = 0.24], **39** (18 mg, 70%) and **38** (6 mg, 24%) were obtained

as colorless oils. $[\alpha]_D^{25} = +10.2$ (*c* = 0.2, CHCl₃). – ¹H NMR: δ = 7.30 (m, 10 H), 5.88 (m, NH), 5.08 [m, CH₂, (Z)], 4.86 (br. s, 1'-H), 4.52 (dd, 2-H), 3.96 (m, 5'-H), 3.84 (m, 4-H), 3.72–3.58 (m, 6-, 1-, 1'', 2'-, 3-H), 3.40 (s, OCH₃), 2.82 (s, NCH₃), 2.45 (dd, 6'a-H), 2.34–2.22 (m, 6'b-, 5 α -H), 2.17 (s, NCH₃), 1.80 (m, 5 β -H), 1.65–1.45 (m, 3'-, 4'-H₂), 1.28 (d, 2''-H); *J*_{1',2'} = 1.9, *J*_{1,2} = *J*_{2,3} = 7.1 Hz. – MS (FAB); *m/z*: 598 (100) [M]⁺, 306 (15) [C₁₇H₂₁N₂O₆ – CO₂, + H]⁺, 289 (10) [C₁₇H₂₁N₂O₅ – CO₂]⁺, 248 (9) [C₁₅H₂₂NO₂]⁺.

3-O-[2',6',6'-[(1*R*)-Phenylethyl]methylamino-3',4',6'-trideoxy- α -D-hexopyranosyl]-1,4,5-trideoxy-6-O-methyl-4-(benzyloxycarbonylamino)-1-(methylamino)-L-chiro-inositol (40): A solution of **39** (15 mg, 0.025 mmol) in 3% methanolic NaOH (3 ml) and water (3 ml) was refluxed for 2 h. After total conversion [TLC, CHCl₃/methanol, 10:1, *R_f* (**39**) = 0.24, *R_f* (**40**) = 0.07], the solution was concentrated in vacuo, diluted with water, and extracted with CH₂Cl₂. Drying (MgSO₄) and concentration in vacuo gave **40** (13 mg, 92%) as colorless oil. $[\alpha]_D^{25} = +39.5$ (*c* = 0.2, CHCl₃). – IR (KBr): $\tilde{\nu}$ = 3398 cm⁻¹ (OH), 1719 (NHCOO), 1509 (NHCOO). – ¹H NMR: δ = 7.30 (m, 10 H), 5.70 (m, NH), 5.08 [m, CH₂, (Z)], 4.82 (br. s, 1'-H), 4.17–4.07 (m, 5'-H, 2-H), 3.99 (m, 4-H), 3.88 (dd, 3-H), 3.65 (q, 1''-H), 3.47 (m, 2'-H), 3.40 (m, 6-H), 3.35 (s, OCH₃), 2.76 (m, 1-H), 2.57 (dd, 6'a-H), 2.49 (s, NCH₃), 2.28–2.18 (m, 6'b-, 5 α -H), 2.21 (s, NCH₃), 2.05–1.65 (m, 5 β -, 4' α -H, 3'-H₂), 1.45 (dddd, 4' β -H), 1.35 (d, 2''-H); *J*_{1',2'} < 1, *J*_{5',6'a} = 7.5, *J*_{6'a,6'b} = 13.5, *J*_{2,3} = *J*_{3,4} = 8.9 Hz. – ¹³C NMR: δ = 157.0 [C=O, (Z)], 136.7 (C_s), 128.5–126.7 (10 C), 98.0 (C-1'), 77.2 (C-2)*, 77.1 (C-2')*, 75.8 (C-3)*, 74.8 (C-6)*, 68.2 (C-5')*, 67.3 (C-4), 66.6 (CH₂, Z), 63.7 (C-1'')*, 63.5 (C-1), 58.1 (C-6'), 56.4 (OCH₃), 40.1 (NCH₃), 34.2 (NCH₃), 29.7 (C-5), 25.4 (C-3'), 23.3 (C-4'), 17.7 (C-2''). – MS (FAB); *m/z* (%): 572 (13) [M + H]⁺, 307 (9) [C₁₆H₂₃N₂O₄]⁺, 289 (8) [C₁₆H₂₃N₂O₄ – H₂O]⁺, 105 (82) [R*]⁺.

3-O-[2',6',6'-[(1*R*)-Phenylethyl]methylamino-3',4',6'-trideoxy- α -D-hexopyranosyl]-1,4,5-trideoxy-6-O-methyl-4-(benzyloxycarbonylamino)-1-(benzyloxycarbonylglycyl)methylamino-L-chiro-inositol (41): Treatment of **40** (13 mg, 0.023 mmol) according to GP 2 [Z-gly-O-suc (9 mg, 0.029 mmol), DMF, 28 h, 60°C] led after chromatography (CHCl₃/methanol, 25:1, *R_f* = 0.18) to **41** (14 mg, 78%) as colorless oil. – ¹H NMR (250 MHz): δ = 7.30 (m, 15 H), 5.30–5.00 [m, 1'-H, 2 CH₂, (Z)], 4.60 (m, 2-H), 4.10 (m, 5'-H), 3.95 (m, 2'-H), 3.80–3.60 (m, 1'', 4-, 6-, 3-, 1-H, CH₂, Gly), 3.40 (s, OCH₃), 2.80 (s, NCH₃), 2.20 (s, NCH₃), 2.50–1.20 (m, 6'a-, 6'b-, 5-H, 4'-, 3'-H₂), 1.47 (d, 2''-H). – MS (FAB); *m/z* (%): 786 (4) [M + Na]⁺, 764 (17) [M + H]⁺, 499 (23) [C₂₆H₃₂N₃O₇]⁺, 248 (17) [C₁₅H₂₂NO₂]⁺.

4-Amino-3-O-(2',6',6'-methylamino-3',4',6'-trideoxy- α -D-hexopyranosyl)-1,4,5-trideoxy-6-O-methyl-1-(glycyl)methylamino-L-chiro-inositol (4): **41** (13 mg, 0.017 mmol) was treated according to GP 3 (8 h) to give **4** (8 mg, 94%) as solid tetrakis(hydrochloride). – ¹H NMR (D₂O, CH₃CN): δ = 5.05 (br. s, 1'-H), 4.20 (m, 2-H), 4.12 (ddd, 6-H), 4.05 (m, 5'-H), 3.95 (m, CH₂), 3.89–3.81 (m, 3-H, 2'-H), 3.74 (m, 4-H), 3.31 (s, OCH₃), 3.10 (dd, 6'a-H), 3.01 (s, NCH₃), 2.98 (dd, 6'b-H), 2.81 (s, NCH₃), 2.50 (dd, 5 β -H), 2.21 (m, 5 α -H), 1.88/1.65 (m, 2 H/1 H, 3'-, 4'- α -H), 1.50 (dddd, 4' β -H); *J*_{1',2'} < 1, *J*_{5',6'a} = 3.0, *J*_{6'a,6'b} = 14.2, *J*_{1,6} = *J*_{5 α ,6} = 10.6, *J*_{4,5 α} = *J*_{5 β ,6} = 4.3, *J*_{5 α ,5 β} = 14.8 Hz. – ¹³C NMR (D₂O, CH₃CN): δ = 93.5 (C-1'), 73.2 (C-3), 71.8 (C-6), 70.2 (C-2), 68.8 (C-2'), 66.0 (C-5'), 56.9 (C-1), 56.4 (OCH₃), 52.7 (C-6'), 48.4 (C-4), 40.9 (CH₂), 34.5 (NCH₃), 31.9 (NCH₃), 29.9 (C-5), 27.3 (C-4'), 22.7 (C-3'). – MS (FAB); *m/z* (%): 413 (5) [M + Na]⁺, 391 (27) [M + H]⁺, 247 (7) [C₁₀H₂₀N₃O₄]⁺, 144 (6) [C₇H₁₄NO₂]⁺.

- [1] C. Ludin, T. Weller, B. Seitz, W. Meier, S. Erbeck, C. Hoenke, R. Krieger, M. Keller, L. Knothe, K. Pelz, A. Wittmer, H. Prinzbach, *Liebigs Ann.* **1995**, 291.
- [2] S. Erbeck, H. Prinzbach, *Tetrahedron Lett.* **1997**, 38, 2653; S. Erbeck, X. Liang, R. Krieger, H. Prinzbach, *Eur. J. Org. Chem.* **1998**, 481; cf. T. Bauer, A. Jezewski, J. Jurczak, *Tetrahedron: Asymmetry*. **1996**, 7, 1405; P. A. Zunszain, O. Varela, *Tetrahedron: Asymmetry*. **1998**, 9, 1269.
- [3] R. Kühlmeier, B. Seitz, T. Weller, H. Fritz, R. Schwesinger, H. Prinzbach, *Chem. Ber.* **1989**, 122, 1729; C. Hoenke, P. Klüwer, U. Hugger, R. Krieger, H. Prinzbach, *Tetrahedron Lett.* **1993**, 34, 4761.
- [4] I. Watanabe, T. Deushi, T. Yamaguchi, K. Kamaiya, M. Nakayama, T. Mori, *J. Antibiot.* **1979**, 32, 1066; T. Deushi, Y. Yamaguchi, K. Kamiya, A. Iwasaki, T. Mizoguchi, M. Nakayama, M. Okuchi, H. Hoh, T. Mori, *J. Antibiot.* **1980**, 33, 1274; D. Ikeda, Y. Horiuchi, M. Yoshida, T. Miyasaka, S. Kondo, H. Umezawa, *Carbohydr. Res.* **1982**, 109, 33.
- [5] J. R. Cox, G. A. McKay, G. D. Wright, E. H. Serpersu, *J. Am. Chem. Soc.* **1996**, 118, 1295.
- [6] D. Ikeda, S. Gomi, M. Hamada, S. Kondo, T. Takeuchi, *Drugs Exptl. Clin. Res.* **1992**, 18, 205.
- [7] C. Ludin, B. Schwesinger, R. Schwesinger, W. Meier, B. Seitz, T. Weller, C. Hoenke, S. Haitz, S. Erbeck, H. Prinzbach, *J. Chem. Soc., Perkin Trans. 1* **1994**, 2685.
- [8] J. Thiem, H. Karl, J. Schwentner, *Synthesis* **1976**, 696; J. Thiem, A. Prahst, I. Lundt, *Liebigs Ann. Chem.* **1986**, 1044; J. Thiem, J. Elvers, *Chem. Ber.* **1980**, 113, 3049.
- [9] E. Nakamura, T. Inubushi, S. Aoki, D. Machii, *J. Am. Chem. Soc.* **1991**, 113, 8980; E. Kawashima, Y. Aoyama, T. Sekine, E. Nakamura, M. Kainosho, Y. Kyogoku, Y. Ishido, *Tetrahedron Lett.* **1993**, 34, 1317; E. Nakamura, Y. Imanishi, D. Machii, *J. Org. Chem.* **1994**, 59, 8178; S. Moutel, J. Prandi, *Tetrahedron Lett.* **1994**, 35, 8163; E. Nakamura, K. Sato, Y. Imanishi, *Synlett*, **1995**, 525; J. Prandi, S. Mayer, *Tetrahedron Lett.* **1996**, 37, 3117.
- [10] R. J. Kinney, W. D. Jones, R. G. Bergmann, *J. Am. Chem. Soc.* **1978**, 100, 7902; A. G. M. Barrett, B. C. B. Bezuidenhout, L. M. Melcher, *J. Org. Chem.* **1990**, 55, 5196; A. G. M. Barrett, L. M. Melcher, B. C. B. Bezuidenhout, *Carbohydr. Res.* **1992**, 323, 259; A. G. M. Barrett, D. J. Rys, *J. Chem. Soc., Chem. Commun.* **1994**, 837; D. L. Boger, J. A. McKie, *J. Org. Chem.* **1995**, 60, 1271.
- [11] B. Seitz, R. Kühlmeier, T. Weller, W. Meier, C. Ludin, R. Schwesinger, L. Knothe, H. Prinzbach, *Chem. Ber.* **1989**, 122, 1745; W. Meier, B. Seitz, C. Hoenke, H. Prinzbach, *Chem. Ber.* **1994**, 127, 1687; J. Schubert, R. Schwesinger, L. Knothe, H. Prinzbach, *Liebigs Ann. Chem.* **1986**, 2009.

[98158]